The Food and Drug Administration recommends that people who consider getting a stem cell treatment need to make sure it has been approved or is being studied in a clinical trial that federal health regulators have allowed. The kind that have generated the most excitement - and controversy - are human embryonic stem cells, which are derived from early human embryos and can be coaxed to become any kind of cell in the body. After 20 years of research, Italian scientists recently received European regulatory approval for a stem cell-based treatment for a type of blindness that results from damage to the cornea, the surface of the eye. The fat tissue was then processed with enzymes with the goal of obtaining stem cells.

However, they immediately suffered complications, including retinal detachment and hemorrhage, which caused total loss of eyesight. "It's just not the case".

None of the women are named in the study.

In 2013, the company listed a trial on ClinicalTrials.gov titled, "Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration", according to the ClinicalTrials.gov site. Both lawsuits were settled, with the women receiving payments.

He warned that patients could be misled by "rogue clinics" which failed to distinguish between the many different types of stem cell. Those efforts have stalled, however. She stated that this was not a drug it was a simple procedure. Albini says the complications could have come from injecting a contaminant into the eye, or from the fact that the stem cells may have turned into myofibroblasts after the injections, which are cells associated with scarring.

The cases show that patients need to be warned that something that "sounds too good to be true may indeed be too good to be true and may even be disgusting", Albini says.

The company appeared to have plans to do more such procedures. Small molecule inhibitors for cancer stem cells in this study are available or being utilized in clinical trials for other diseases. The two women told Albini that they did not recall signing documents other than the single page form.

"Patients and physicians in the United States should be made aware that not all "stem cell" clinics are safe, and that "stem therapy" as provided in private clinics in the U.S. is unproven and potentially harmful", says Thomas Albini at the University of Miami's Bascom Palmer Eye Institute, Florida, who subsequently treated two of the women.

Each woman paid $5,000 for the procedure.

The doctors say patients should also check if anything purporting to be a clinical trial is affiliated with an academic medical centre and inform themselves about stem cell treatments.

"These women had fairly functional vision prior to the procedure. and were blinded by the next day", said ophthalmologist Dr Thomas Albini of the University of Miami, whose team examined the women after their treatment at a clinic in Florida. In the case of the eye injections, the clinic injected both eyes at once, which is highly unusual and unsafe for an experimental treatment.

The trial was not preceded by laboratory experiments and lacked comparison between treated patients and "control group" participants given a dummy therapy.

It's still not clear what went wrong, but the report says the treatment raised several red flags from the beginning.

But even if executed correctly, there is no evidence suggesting that the procedure could help restore vision, Goldberg and Albini said. A year later, the patient suffered none of the additional vision loss that would be common with the condition. iPS stem cells have a body of research behind their potential healing abilities, while the fat-based cells used in the procedures do not. It offers stem cell treatments for a variety of diseases and injuries, according to the company's website.

"With this new and exciting study, Dr. Wang and his team have provided the building blocks for understanding the cellular and genetic mechanisms behind squamous cell carcinoma", said Dr. Paul Krebsbach, dean of the UCLA School of Dentistry. "Doing the procedure in rats might have shown whether there are safety problems".

Without regulation of stem cell isolation and delivery processes at stem cell clinics, it's hard to know whether their cocktails contain harmful chemicals leftover from the isolation process - or whether they contain stem cells at all. In a regulatory filing, it reported that its techniques can treat chronic obstructive pulmonary disease, hip and knee conditions, diabetes, multiple sclerosis, Parkinson's disease, autism, colitis, and lupus.

Excerpt from:
Unproven Stem Cell Treatment Blinds 3 Florida Women - ClickLancashire

IPS Cell Therapy Comments Off on Unproven Stem Cell Treatment Blinds 3 Florida Women – ClickLancashire | March 26th, 2017

Scientists used stem cells to grow human heart tissue that contracted spontaneously in a petri dish marking progress in the quest to manufacture transplant organs.

A team from the University of Pittsburgh, Pennsylvania, used induced pluripotent stem (iPS) cells generated from human skin cells to create precursor heart cells called MCPs. iPS cells are mature human cells reprogrammed into a versatile, primitive state from which they can be prompted to develop into any kind of cell of the body. The primitive heart cells created in this way were attached to a mouse heart scaffold from which the researchers had removed all mouse heart cells, they wrote in the journal Nature Communications.

The scaffold is a network of non-living tissue composed of proteins and carbohydrates to which cells adhere and grow on. Placed on the 3D scaffold, the precursor cells grew and developed into heart muscle, and after 20 days of blood supply the reconstructed mouse organ began contracting again at the rate of 40 to 50 beats per minute, said a University of Pittsburgh statement.

It is still far from making a whole human heart, added senior researcher Lei Yang. Ways have to be found to make the heart contract strongly enough to pump blood effectively and to rebuild the hearts electrical conduction system. However, we provide a novel resource of cells iPS cell-derived MCPs for future heart tissue engineering, Yang told AFP by email. We hope our study would be used in the future to replace a piece of tissue damaged by a heart attack, or perhaps an entire organ, in patients with heart disease.

According to the World Health Organisation, an estimated 17 million people die of cardiovascular ailments every year, most of them from heart disease. Due to a shortage of donor organs, end-stage heart failure is irreversible, said the study. More than half of patients with heart disease do not benefit from drugs. Heart tissue engineering holds a great promise based on the reconstruction of patient-specific cardiac muscle, the researchers wrote.

Last month, scientists in Japan said they had grown functional human liver tissue from stem cells in a similar process. Creating lab-grown tissue to replenish organs damaged by accident or disease is a Holy Grail for the pioneering field of stem cell research. Until a few years ago, when iPS cells were created, the only way to obtain stem cells was to harvest them from human embryos. This was controversial because it required the destruction of the embryo, a process to which religious conservatives and others object.

Source: http://news.sudanvisiondaily.com

As the Chief Doctor of the Institute of Cell Therapy, Y.V.Gladkikh, MD, PhD, Dr. med. sc. commented: In addition to laboratory success in obtaining the functional cardiac tissue, currently there is evidence of successful implantations of heart valves and blood vessels fragments, grown from stem cells, to patients. And in 2012, the Ministry of Health of Ukraine officially approved method of treatment of critical limbs ischemia with the use of cell preparation Angiostem, developed by the biotechnological laboratory of the Institute of Cell Therapy.

See original here:
Scientists know how to grow human heart tissue - Institute ...

IPS Cell Therapy Comments Off on Scientists know how to grow human heart tissue – Institute … | March 25th, 2017

Before we get to the therapeutic stuff, here is a reminder of the main problem people with Parkinsons disease face.

Researchers are reasonably sure that the accumulation of a protein called alpha-synuclein is responsible for neurons dying in people with PD. However, there are two competing theories as to how it builds up andspreads,the threshold theoryandthe ascending theory(also called the prion hypothesis). The ascending theory states that alpha-synuclein spreads from cell to cell, infecting cells as the protein moves up through the brain.The threshold theory recently put forward by Dr. Ole Isacson and Dr. Simone Engelender, proposes that alpha-synuclein builds up independently in each affected cell.

Regardless, an improved understanding of exactly how such proteins misfold and clump together is at the heart of the riddle that is Parkinsons as well asa long list of other diseases. Thankfully a number of labs around the world have been working on this sticky problem. Additionally, if anyone wants to help you can do so very easily from any computer, watch this video to learn how.

The ongoing revolution in genetics is playing an increasingly important role in our understanding of the disease while also revealing whyit varies so much from patient to patient. There havebeen dozens of mutations and variants associated so far with the disease. We are just beginning to understand the role our genes play in the development of neurological diseases but an immense amount of progress has been made in the last 15 years since the human genome was sequenced. Now that sequencing costs have plummeted to around a thousand dollars we are on the verge of a new era in medicine that promises to give patients treatments tailored to their specific condition.

Personalized medicine is healthcare based on your unique genetic and molecular blueprint. Each individual has distinct genetic makeup, biomolecule and metabolic profiles, set of gut microbes, and so on. Similarly, there is no one-size-fit-all in healthcare. How you stay healthy or how you are treated for disease should be catered to match your unique profile. Knowledge of your genomics, proteomics, metabolomics, microbiotics, and other bioinformatics allow for the improvement in the quality of life, from disease prevention to therapy best suited to you. (from the Personalized Medicine Initiative in British Columbia.)

A better understanding ofgeneticswill help unlock a cascade of other problems that surround this disease includingmitochondrial dysfunction, lysosomal degradation, neuroinflammation,gut bacteria, andepigenetics, among others. And thankfully there is now a large interconnected global community of researchers working to solve these problems with more resources and better tools than in all of human history combined. This growth in a variety of public and private sector health initiatives across disciplines has lead a growing number of experts to believe that we will make more progress in the next decade than we did in the past century, which is good reason to be hopeful consideringwhat medicine was like a hundred years ago.

This medical revolution will be further bolstered by new and improved imaging techniques.A big part of the problem we still have with this disease is that we cant actually see what is wrong. Every person who has PDhas slightly different symptoms but we dont really know why primarily because we cant accurately see inside patients heads. Soon a new line of imaging techniques will be available that will give surgeons and researchers a much better understanding of what is going on inside the heads of each patient.

In addition, there are some immense ongoing collaborations such as theEuropean human brain projectand theU.S. brain initiativethat are trying to do for the brain what the human genome project did for our understanding of the genome. If successful it will give researchers unprecedented insight into how our minds are pieced together.

Then there are the new therapies themselves.

Levadopa For 50 years now this wonder drug has brought relief to millions. Of course, problems still persist, namely in getting it past that stubborn blood brain barrier and making sure a more steady supply is delivered to reduce on/off fluctuations. To get around some of those problems we now havepatches, slow release and extended release capsules, as well asintestinal pumps that deliver a steady flow of the drug directly into the intestines. Of course this drug is not an ideal solution as there are nasty side effects that come from long term use, predominantly dyskenisia which gives people the motor control of a blob of jelly, but for now, it is still the best stop-gap solution we have.

Deep Brain Stimulation This science-fiction wonder has become the undisputed Queen of modern treatments. It has already proven itself to be a miracle worker, re-animating hundreds of thousands with its electric wizardry. It too is steadily improving, from John Palfermans book,Brain Storms,Instead of implanting devices that simply deliver a continuous electrical stimulation, they are developing technologies that deliver stimulating jolts only when required. ..The idea is to design DBS so that the system can monitor the electrical activity in the basal ganglia, and when it detects an abnormal signal, it can respond automatically with an appropriate stimulation. A smart device

New Drugs There is along list of promising drugs that are already in clinical trial.Some of these drugs have the potential to not only offer symptomatic relief but hit the holy grail that is actual disease modifying therapies.

Neuromodulation techniques A number of novelneuromodulation techniques are being tested for clinical use. The most prevalent is called transcranialmagnetic stimulation in which magnets are attached to the outside of patients headsthat send a focused electric current deep into the target areas of the brain. Already an approved therapy for depression, TMS is now being tried in PD.

Immunotherapies The relatively recent identification of alpha-synuclein as playing a key role in disease formation has lead researchers to believe that we may be able to harness the bodies immune system to stop the protein from clumping while also mitigating the bodies natural inflammatory responses that damages neurons.

Pharmacogenetics The genetic revolutionhas spurred the development of a relatively new field of pharmacology called pharmacogenetics. Eventually, instead of making one drug for everybody, we will be able to tailor drugs to better fit each persons unique condition.

Stem Cell Therapies Though there were a series of trials in the 90s that had mixed results, recently a number of labs around the world have begun reexamining the therapeutic potential of stem cells. This is thanks in part to the 2007 discovery of anew type of stem cell called IPS cells which allow researchers to grow fully functioning stem cells from patients own skin cells. This has opened the door to a new set of therapies while also giving us better disease models. Since those first trials we have also made a series of other advances in our understanding of how to use stem cells which has lead to somestunning results in trials on other apes. Some labsare hoping to push forward with human trials starting at the end of this year.

Gene Modification Therapies As discussed earlier, the field of genetics is blowing up and one of the biggest benefits to society that will come from it is a new set of therapies called gene modification therapies.The most popular one today is called CRISPR, a technique that already allows researchers to cut and paste genetic code, changing the genome of living organisms. A number of articles have come out touting these kind of gene-editing techniques as the future of medicine. This first use ofCRISPRwas in a lung cancer patient in Chinalast fall, but it is also being used to help us understand neurodegenerative disordersincludingParkinsons disease.

Direct Programming In conjunction with gene therapy, direct programming is believed to bethe final solution to the problem of neurodegeneration. It is a subset of the new field of synthetic biologythatwill eventually allow us to change cell types in living organisms. For example, inpeople with Parkinsons disease we will be able toreprogram other healthy cells in the affected area, such as glial cells or astrocytes, and directly turn them into dopamine-producing cells.

When it comes right down to it, the reason why we have not been able to cure a lot of the diseases that are still with us today, such as neurodegeneration or cancer, is that there are an incredible number of factors to consider when trying to treat them, possibly too many for any human, or even any group of humans, to make sense of. But there might be a solution to this problem as we are now figuring out ways to export more and more of our intellectual abilities into computers. Already computers have become as good ashumans at diagnosing certain conditions, and astaggering number of healthcare companieshave now invested heavily in applyingartificial intelligence to the medical industry.This, along with further advances in nanotechnology,has a lot of potentialin helping us understand diseases such as Parkinsons and may reveal novel insights into how to treat them.

As you can see, there is plenty in the pipeline. While there may not be any magic bullet, there is no doubt that we will continue to see improvements in the treatment of Parkinsons disease that will benefit millions. While it is important to remain skeptical of all the promises being made, there is very good reason to believe that afflictions such as Parkinsons disease may one day be a thing of the past.

More here:
We're About to Enter a New Era in Parkinson's Disease Treatments - Futurism

IPS Cell Therapy Comments Off on We’re About to Enter a New Era in Parkinson’s Disease Treatments – Futurism | March 24th, 2017

A two-step method to make microglia Nature.com Microglia have been reported in some disease models to have beneficial effects; however, research into their potential as a cell therapy is limited by the lack of means to produce readily grafted, autologous microglial cells. Now, in Nature ...

See the rest here:
A two-step method to make microglia - Nature.com

IPS Cell Therapy Comments Off on A two-step method to make microglia – Nature.com | March 23rd, 2017

Abnormal development of the brain in an intractable disease, thanatophoric dysplasia Science Daily It is only possible, by using appropriate animal model that reproduces relevant pathophysiology, to uncover the process of pathogenesis and to develop therapy. Since the research on abnormalities of bones in TD is progressing with iPS cells at Kyoto ...

Read more:
Abnormal development of the brain in an intractable disease, thanatophoric dysplasia - Science Daily

IPS Cell Therapy Comments Off on Abnormal development of the brain in an intractable disease, thanatophoric dysplasia – Science Daily | March 19th, 2017

iPS cells may help halt failing vision

Getty

By Andy Coghlan

A woman in her 80s has become the first person to be successfully treated with induced pluripotent stem (iPS) cells. A slither of laboratory-made retinal cells has protected her eyesight, fighting her age-related macular degeneration a common form of progressive blindness.

Such stem cells can be coaxed to form many other types of cell. Unlike other types of stem cell, such as those found in an embryo, can be made from adult non-stem cells a discovery that in 2012.

Now, more than a decade after they were created, these stem cells have helped someone. at the RIKEN Laboratory for Retinal Regeneration in Kobe, Japan, and her team took skin cells from the woman and turned them into iPS cells. They then encouraged these to form retinal pigment epithelial cells, which are important for supporting and nourishing the retina cells that capture light for vision.

The researchers made a slither of cells measuring just 1 by 3 millimetres. Before in 2014, they first removed diseased tissue on her retina that was gradually destroying her sight. They then inserted the small patch of cells they had created, hoping they would become a part of her eye and stop her eyesight from degenerating.

Now the results are in. Published today, they show that the treatment hasnt made the womans vision any sharper, but it does seem to have prevented further deterioration with her vision now stable for more than two years. Since the graft, the woman says her vision is brighter.

Takahashi and her team have done incredible work, and deserve all the praise they get for this project, says , director of the Center for iPS Cell Research and Application at Kyoto University, who won the Nobel prize for and collaborated on this work. This is a landmark study and opens the door to similar treatments for many diseases, he says.

This first iPSC-derived retinal graft is an important landmark in the field of retinal regeneration, says at University College London, and head of a trial at Moorfields Eye Hospital in London of similar grafts made instead from human embryonic stem cells.

One worry about this approach is that turning the stem cells into new tissues could lead to cancer-causing genetic mutations though the team found no evidence of this in the treated woman. However, a trial of the technique in another person was cancelled in 2015, after tests revealed that the cells intended to be given to the man had developed genetic abnormalities.

But although it has taken many years to bring , many private centres around the world have been advertising unregulated treatments purporting to use stem cells for some time.

A second study published today shows just how badly some unregulated treatments described as stem cell therapies can go wrong. Three case reports of women given such treatments for age-related macular degeneration detail how one woman went blind and the vision of the other two became much worse.

All three ended up seeking emergency treatment in 2015, after each paid $5000 to a private clinic to receive injections of their own fatty tissue into their eyes.

Patients and physicians in the US should be made aware that not all stem cell clinics are safe, and that stem therapy as provided in private clinics in the US is unproven and potentially harmful, says at the University of Miamis Bascom Palmer Eye Institute, Florida, who subsequently treated two of the women.

Albini advises people to be suspicious of any procedure involving payment. Most legitimate research in the US does not require patients to pay for the experimental procedures, he says, adding that people should check whether a trial has been registered with the US Food and Drug Administration. Be aware that if it sounds too good to be true, it may indeed not be true.

Journal reference: New England Journal of Medicine, DOI: ;

:

More on these topics:

Read more:
Vision saved by first induced pluripotent stem cell treatment ... - Concord Register

IPS Cell Therapy Comments Off on Vision saved by first induced pluripotent stem cell treatment … – Concord Register | March 19th, 2017

Masayo Takahashi (second from left) treated macular degeneration with retinal tissue grown from iPS cells.

Kyodo News/Contributor/getty images

By Dennis NormileMar. 15, 2017 , 5:00 PM

Its official: The first use of induced pluripotent stem (iPS) cells in a human has proved safe, if not clearly effective. Japanese researchers reported in this weeks issue of The New England Journal of Medicine (NEJM) that using the cells to replace eye tissue damaged by age-related macular degeneration (AMD) did not improve a patients vision, but did halt disease progression. They had described the outcome at conferences, but publication of the details is an encouraging milestone for other groups gearing up to treat diseased or damaged organs with the versatile replacement cells, which are derived from mature tissues.

This initial success is pretty momentous, says Alan Trounson, a stem cell scientist at the Hudson Institute of Medical Research in Melbourne, Australia. But the broader picture for iPS therapies is mixed, as researchers have retreated from their initial hopes of creating custommade stem cells from each patients tissue. That strategy might have ensured that recipients immune systems would accept the new cells. But it proved too slow and expensive, says Shinya Yamanaka of Kyoto University in Japan, who first discovered how to create iPS cells and is a co-author of the NEJM paper. He and others are now developing banks of premade donor cells. Using stocks of cells, we can proceed much more quickly and cost effectively, he says.

Even so, clinical work is progressing more quickly than I had expected, says Yamanaka, who did his groundbreaking work just a decade ago. His collaborator on this trial, Masayo Takahashi of the RIKEN Center for Developmental Biology in Kobe, Japan, had a head start. An ophthalmologist, Takahashi was familiar with the ravages of AMD, a condition that progressively damages the macula, the central part of the retina, and is the leading cause of blindness in the elderly.

Takahashi started investigating treatments for AMD in 2000, a time when the only cells capable of developing into all the tissues of the body had to be extracted from embryos. But she was stymied by immune reactions to these embryonic stem (ES) cells. When Yamanaka announced that he could induce mature, or somatic cells, to return to an ES celllike state, Takahashi quickly changed course to develop a treatment based on iPS cells.

Her team finally operated on the first patient, a 77-year-old Japanese woman with late-stage AMD, in September 2014. They took a sample of her own skin cells, derived iPS cells, and differentiated them into the kind of retinal cells destroyed by the disease. A surgeon then slipped a small sheet of the cells into the retina of her right eye.

An operation on a second patient was called off because a number of minor genetic mutations had crept into his iPS cells during processing, and uncontrolled growthcancerhas been a worry with such cells. These changes do not directly induce cancer, but we wanted to make safety the first priority, Yamanaka says. Also, Takahashi says, AMD drugs had stabilized the patients condition so there was no urgency in subjecting him to the risks of surgery, which include hemorrhaging and retinal damage.

Immediately after surgery the first patient reported her eyesight was brighter. Takahashi says the surgery halted further deterioration of her eye, even without the drug injections still being used to treat her other eye, and there were no signs of rejection of the graft as of last December.

Clinical work is progressing much more quickly than I expected.

The result is a proof of principle that iPS cellbased therapy is feasible, says Kapil Bharti, a molecular cell biologist at the U.S. National Institutes of Healths National Eye Institute in Bethesda, Maryland, who is also developing iPS cells for treating AMD. Takahashi says once her team gains more experience with the technique they will extend it to patients with earlier-stage AMD in an effort to preserve vision.

Last month, Takahashi won approval to try the procedure on another five patients with late-stage AMD. But this time, instead of using iPS cells derived from each patient, the team will draw on banked cells from a single donor. It takes time to create iPS cells, and a lot of time for the safety evaluation, Yamanaka says. It is also costly, at nearly $900,000 to develop and test the iPS cells for the first trial, Takahashi adds.

Using donor cells to create the iPS cells will make it more difficult to ensure immune compatibility. But Yamanaka says that donor iPS cells can be matched to patients based on human leukocyte antigen (HLA) haplotypessets of cell-surface proteins that regulate immune reactions. HLA-matched cells should require only small doses of immunosuppressive drugs to prevent rejection, Takahashi saysand perhaps none at all for transplantation into the immune-privileged eye.

Kyoto Universitys Center for iPS Cell Research and Application, which Yamanaka heads, has been developing an iPS cell bank. Just 75 iPS cell lines will cover 80% of the Japanese population through HLA matching, he says. Trounson, a past president of the California Institute for Regenerative Medicine, a stem cell funding agency, says banked iPS cells have advantages. Donor iPS cells may be safer than cells derived from older patients, whose somatic cells may harbor mutations. And Jordan Lancaster, a physiologist at the University of Arizona in Tucson, likes the speed of the approach. He is devising patches for heart failure patients based on iPS-derived myocardial cells that will be premanufactured, cryopreserved, and ready to use at a moments notice.

Patient-specific iPS cells will still have clinical uses. For one thing, Bharti says it will be difficult for cell banks to cover all HLA haplotypes. And a patients own iPS cells could be used to screen for adverse drug reactions, says Min-Han Tan, an oncologist at Singapores Institute of Bioengineering and Nanotechnology, who recently published a report on the approach.

Other human trials are not far behind. Yamanaka says his Kyoto University colleague Jun Takahashi (Masayo Takahashis husband) will launch trials of iPS-derived cells to treat Parkinsons disease within 2 years. Bharti hopes to start human trials of iPS cells for a different type of macular degeneration next year. And as techniques for making and growing iPS cells improve, researchers can contemplate treatments requiring not just 100,000 cells or sothe number in Takahashis retinal sheetsbut millions, as in Lancasters heart patches.

As clinical use approaches, Takahashi cautions that researchers need to keep public expectations realistic. For now, iPS treatments may help but wont fully reverse disease, she says. Regenerative medicine is not going to cure patients in the way they hope.

Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Continue reading here:
Cutting-edge stem cell therapy proves safe, but will it ever be effective? - Science Magazine

IPS Cell Therapy Comments Off on Cutting-edge stem cell therapy proves safe, but will it ever be effective? – Science Magazine | March 18th, 2017

The new report says the three women, in their 70s and 80s, paid $5,000 to be treated in 2015 for age-related macular degeneration. Participants can also report their concerns to the Office for Human Research Protections within the U.S. Department of Health and Human Services.

The "devastating outcomes" experienced by the women raise the "need for oversight of such clinics and for the education of patients by physicians and regulatory bodies", the paper said.

The women all suffered detached retinas, vision loss, and hemorrhages in their eyes.

"We don't mean to say all stem cell clinical studies are risky", coauthor Dr. Thomas Albini of the University of Miami told Reuters Health in a telephone interview.

Paul Knoepfler, a stem-cell scientist at the University of California at Davis who is a frequent critic of the clinics, said he didn't understand why the FDA and the NIH have not moved more aggressively to ensure patient safety. They sought treatment at a Florida clinic that had announced a study to treat the condition on clinicaltrials.gov, a federal database of research studies. Two out of the three patients found the trial through the website, which doesn't fully vet trials for scientific soundness. "Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms", said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld. Stem cell clinics have cropped up all over the United States in recent years and are operating in a self-perceived regulatory loophole. Stem cells were then extracted from the fat and injected into their eyes. Albini says the complications could have come from injecting a contaminant into the eye, or from the fact that the stem cells may have turned into myofibroblasts after the injections, which are cells associated with scarring.

The Japanese case marks the first time anyone has given induced pluripotent stem (iPS) cells to a patient to treat any condition.

Legitimate medical research seldom requires patients to pay and, in the case of eye treatments, only one eye is treated at a time so doctors can gauge its effectiveness, the Kuriyan team said.

Although the women had moderate vision loss prior to the stem cell treatments, a year later their vision ranged from total blindness to 20/200, which is considered legally blind.

And even if the interventions were done well, they say, there is no evidence that they could have restored the patients' vision. They first cultivate stem cells to form the retinal pigmented epithelial cells that are needed to restore a damaged retina.

Shoddy stem cell preparation may have led to some of the complications, said the study authors.

The episode, described Wednesday in an article in the New England Journal of Medicine, represents one of the most egregious examples of patient injury involving a stem-cell clinic. The company also noted that it does not now treat eye patients.

The paper also mentions that the women believed that they were taking part in a clinical trial because they were aware of the clinic's work on the ClinicalTrials.gov website run by the U.S. National Library of Medicine. In other words, the company claims the study was stopped before patients were enrolled. In fact, doctors have done bone marrow transplant, a procedure where stem cell transplantation is performed.

"There's this perception that there are all these stem cell therapies out there that are close to clinical application that. are being held back by regulators and if they just step back, there would be all these treatments", he said. However, it can be hard for patients to distinguish between trials that are legitimate, and those that are not, the authors wrote.

"There's no excuse for not designing a trial properly and basing it on preclinical research", added study Jeffrey Goldberg, also a study author, of Stanford University's School of Medicine.

Researchers from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg and an global team have now identified an ingenious mechanism by which the body orchestrates the regeneration of red and white blood cells from progenitor cells.

See if a trial is affiliated with an academic medical center - that's a good sign it is legitimate, they say.

Read the original here:
3 women blinded after receiving stem cell therapy for macular degeneration - ClickLancashire

IPS Cell Therapy Comments Off on 3 women blinded after receiving stem cell therapy for macular degeneration – ClickLancashire | March 18th, 2017

Luxembourg (Scicasts) Stem cells are unspecialized cells that can develop into any type of cell in the human body. So far, however, scientists only partially understand how the body controls the fate of these all-rounders, and what factors decide whether a stem cell will differentiate, for example, into a blood, liver or nerve cell. Researchers from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg and an international team have now identified an ingenious mechanism by which the body orchestrates the regeneration of red and white blood cells from progenitor cells. "This finding can help us to improve stem cell therapy in future," says Dr. Alexander Skupin, head of the "Integrative Cell Signalling" group of LCSB. The LCSB team has published its results in the scientific journal PLOS Biology.

Although all cells in an organism carry the same genetic blueprints -- the same DNA -- some of them act as blood or bone cells, for example, while others function as nerve or skin cells. Researchers already understand quite well how individual cells work. But how an organism is able to create such a diversity of cells from the same genetic template and how it manages to relocate them to wherever they are needed in the body is still largely unknown.

In order to learn more about this process, Alexander Skupin and his team treated blood stem cells from mice with growth hormones and then watched closely how these progenitor cells behaved during their differentiation into white or red blood cells. The researchers observed that the cells' transformation does not occur in linear, targeted fashion, but rather more opportunistically. Each progenitor cell adapts to the needs of its environment and integrates itself into the body where new cells are needed. "So, it is not as though the cell takes a ticket at the beginning of its differentiation and then travels straight to its destination. Rather, it gets off frequently to look around and see which line is best to take," Alexander Skupin explains. By this clever mechanism, a multicellular organism can adapt the regrowth of new cells to its current needs. "Before progenitor cells differentiate once and for all, they first lose their stem cell character and then check, as it were, which cell line is currently in demand. Only then do they develop into the cell type that best suits their characteristics and which prevails in their environment," Alexander Skupin says.

The researcher likens this step to a game of roulette, where the different types of cells can be thought of as the differently numbered slots in the roulette wheel that catch the ball. "When the cells lose their stem cell character, they are quasi thrown into the roulette wheel, where they first bounce around aimlessly. Only when they have found the right environment do the cells then drop into that niche - like the roulette ball falling into a numbered slot - and differentiate definitively." This way, the body can orchestrate its cell regeneration and at the same time prevent stem cells from being misdirected too early. "Even if a cell takes a wrong turn, it is ultimately sorted out again if its characteristics are unsuitable for the niche, or slot, it has landed in," says Skupin.

With their study, Alexander Skupin and his team have shown for the first time that a progenitor cell's fate is not clearly predetermined and does not follow a straight line. "This observation contradicts the current doctrine that stem cells are programmed to follow a certain lineage from the beginning," Alexander Skupin says. The researcher is furthermore convinced that the processes are similar for other progenitor cells. "In the lab, we have observed the same differentiation pattern in so-called iPS cells, or induced pluripotent stem cells, which can transform into many different types of cells."

This knowledge can help the researchers to improve the effectiveness of therapies in future. Stem cell therapy involves administering a patient his or her own body's stem cells in order to replace other cells that have died as a result of an affliction such as Parkinson's disease. While this promising treatment method has been intensively researched over many years, there has so far been only limited practical success in endogenous stem cell therapy. It is also highly controversial, since it is frequently accompanied by severe side effects and it cannot be ruled out that some cells might degenerate and lead to cancer. "Because we now have a better understanding of how the body influences the direction in which stem cells differentiate, we can hopefully control this process better in future," Alexander Skupin concludes.

Article adapted from a University of Luxembourg news release.

Publication: Cell Fate Decision as High-Dimensional Critical State Transition. Mitra Mojtahedi et al. PLoS Biol. (2016): Click here to view.

Read more:
Team Deciphers How the Body Controls Stem Cells - Scicasts (press release) (blog)

IPS Cell Therapy Comments Off on Team Deciphers How the Body Controls Stem Cells – Scicasts (press release) (blog) | March 18th, 2017

March 17, 2017 Left: Cross-sectional view of the cerebrum in normal ferret. Neurons are localized in the cerebral cortex, the surface layer of the cerebrum. Since the surface of the cerebrum has folds (gyri), the layer containing neurons winds on its way. Right: Cross-sectional view of the cerebrum in TD ferret. Clusters of neurons (indicated by arrows) are found deep in the cerebrum, which are not detected in the cerebrum of normal ferret. They are called 'periventricular nodular heterotopia,' PNH. In addition, in the surface layer, a larger number of smaller folds (gyri) are seen than normal (indicated by asterisks). They are called polymicrogryri. Credit: Kanazawa University

Thanatophoric dysplasia (TD) is an intractable disease causing abnormalities of bones and the brain. In a recent study of ferrets, which have brains similar to those of humans, researchers using a newly developed technique discovered that neuronal translocation along radial glial fibers to the cerebral cortex during fetal brain development is aberrant, suggesting the cause underlying TD.

In TD cases, the limb and rib bones are shorter than normal, and brain abnormalities manifest, including polymicrogyria and periventricular nodular heterotopia. Previous research has determined that a gene, fibroblast growth factor receptor 3 (FGFR3), is responsible. However, as a result of TD rarity and the difficulty of obtaining brain samples from human patients, the pathophysiology of TD is largely unknown, and effective therapy has not been established.

The present research team of Kanazawa University generated an animal model of TD using ferrets that reproduces the brain abnormalities found in human TD patients. By using this animal model, the team elucidated the formation process of polymicrogyria, one of the abnormalities found in the TD brain. The team has also investigated the formation process of PNH, the other brain abnormality found in human TD patients.

First, PNH was analyzed in terms of composing cell types to reveal that a large number of neurons but few glial cell exist in PNH. In a healthy brain, neurons are found in the cerebral cortex near the brain surface. The researchers believe that during fetal brain development, PNH formation might be induced by the inability of neurons to translocate themselves to the cerebral cortex. The researchers found that the spatial arrangement of radial glial cells was distorted; radial glial fibers are believed to serve as the "track" for neurons to translocate themselves. Thus, the distortion of radial glial fibers seems to be a reason for aberrant localization of neurons.

Research on abnormalities of bones in TD is progressing with iPS cells at Kyoto University, and it is expected that the whole aspect of TD with brain and bone abnormalities would be elucidated and that the therapeutic methods would be developed. The present study on PNH was only possible using the experimental technique for ferrets developed by the research team. This animal model technique could also contribute to studies of other neurological diseases that have been difficult to investigate with conventional model animals.

Explore further: Researchers discover a gene's key role in building the developing brain's scaffolding

More information: Naoyuki Matsumoto et al, Pathophysiological analyses of periventricular nodular heterotopia using gyrencephalic mammals, Human Molecular Genetics (2017). DOI: 10.1093/hmg/ddx038

(Medical Xpress)Researchers have pinpointed the role of a gene known as Arl13b in guiding the formation and proper placement of neurons in the early stages of brain development. Mutations in the gene could help explain ...

A protein that may partly explain why human brains are larger than those of other animals has been identified by scientists from two stem-cell labs at UC San Francisco, in research published in the November 13, 2014 issue ...

Today, a stroke usually leads to permanent disability but in the future, the stroke-injured brain could be reparable by replacing dead cells with new, healthy neurons, using transplantation. Researchers at Lund University ...

Research on fragile X syndrome, the most common inherited cause of mental retardation, has focused mostly on how the genetic defect alters the functioning of neurons in the brain. A new study focusing on a different type ...

Zika's hypothesized attraction to human neural stem cells may come from its ability to hijack a protein found on the surface of these cells, using it as an entryway to infection. In Cell Stem Cell on March 30, researchers ...

The difference between an old brain and a young brain isn't so much the number of neurons but the presence and function of supporting cells called glia. In Cell Reports on January 10, researchers who examined postmortem brain ...

The majority of genes associated with nephrotic syndrome (NS) in humans also play pivotal roles in Drosophila renal function, a conservation of function across species that validates transgenic flies as ideal pre-clinical ...

Britain's Newcastle University says its scientists have received a license to create babies using DNA from three people to prevent women from passing on potentially fatal genetic diseases to their childrenthe first time ...

Columbia University Medical Center (CUMC) researchers have discovered a common genetic variant that greatly impacts normal brain aging, starting at around age 65, and may modify the risk for neurodegenerative diseases. The ...

Studies of autoimmune and inflammatory diseases have identified hundreds of genetic regions thought to be associated with these conditions. At the same time, studies of expression quantitative trait loci (eQTLs) have revealed ...

Scientists studying the role of a protein complex in the normal development of the mouse brain unexpectedly created a mouse model that replicates clinical symptoms of patients with complex neurological disorders such as hyperactivity, ...

Genetic variation in the non-coding DNA could give rise to language impairments in children and other neurodevelopmental disorders including schizophrenia, autism, and bipolar disorder, scientists from the Max Planck Institute ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the rest here:
Researchers develop new animal model to study rare brain disease - Medical Xpress

IPS Cell Therapy Comments Off on Researchers develop new animal model to study rare brain disease – Medical Xpress | March 18th, 2017

Scientists have long hoped that stem cells might have the power to treat diseases. But it's always been clear that they could be dangerous too, especially if they're not used carefully.

Now a pair of papers published Wednesday in the New England Journal of Medicine is underscoring both the promise and the peril of using stem cells for therapy.

In one report, researchers document the cases of three elderly women who were blinded after getting stem cells derived from fat tissue at a for-profit clinic in Florida. The treatment was marketed as a treatment for macular degeneration, the most common cause of blindness among the elderly. Each woman got cells injected into both eyes.

In a second report, a patient suffering from the same condition had a halt in the inexorable loss of vision patients usually experience, which may or may not have been related to the treatment. That patient got a different kind of stem cell derived from skin cells as part of a carefully designed Japanese study.

The Japanese case marks the first time anyone has given induced pluripotent stem (iPS) cells to a patient to treat any condition.

"These two reports are about as stark a contrast as it gets," says George Q. Daley, Harvard Medical School's dean and a leading stem cell researcher. He wrote an editorial accompanying the two papers. "It's really striking."

The report about the three women in their 70s and 80s who were blinded in Florida is renewing calls for the Food and Drug Administration to crack down on the hundreds of clinics that are selling unproven stem cell treatments for a wide variety of medical conditions, including arthritis, autism and stroke.

"One of the big mysteries about this particular case and the mushrooming stem cell clinic industry more generally is why the FDA has chosen to effectively sit itself out on the sidelines even as this situation overall grows increasingly risky to patients," says Paul Knoepfler, a University of California, Davis, stem cell researcher who has studied the proliferation of stem cell clinics.

"The inaction by the FDA not only puts many patients at serious risk from unproven stem cell offerings, but also it undermines the agency's credibility," Knoepfler wrote in an email.

In response to a query from Shots, an FDA spokeswoman wrote in an email that the agency is in the process of finalizing four new guidelines aimed at clarifying how clinics could use stem cells as treatments. The agency also noted that it had previously issued a warning to patients.

In the meantime, "consumers are encouraged to contact FDA and the appropriate state authorities in their jurisdictions to report any potentially illegal or harmful activity related to stem cell based products," the FDA email says.

Other researchers say the cases should stand as a warning to patients considering unproved stem cell treatments, especially those tried outside carefully designed research studies.

"Patients have to be wary and tell the difference between the snake oil salesmen who are going to exploit them and the kind of slow, painstaking legitimate clinical trials that are also going on," Daley says.

The New England Journal of Medicine report did not name the Florida clinic, but noted that the treatment was listed on a government website that serves as a clearinghouse for research studies. The sponsor is listed as Bioheart, Inc., which is part of U.S. Stem Cell Inc. in Sunrise, Fla.

Kristen Comella, the scientific director of U.S. Stem Cell, would not discuss the cases. "There were legal cases associated with eye patients that were settled under confidentiality, so I am not permitted to speak on any details of those cases due to the confidentiality clause," Comella said by phone.

She acknowledged, however, that the clinic had been performing the stem cell procedures. They were discontinued after at least two patients suffered detached retinas, she says.

But Comella defended the use of stem cells from fat tissue to treat a wide variety of other health problems.

"We have treated more than 7,000 patients and we've have had very few adverse events reported. So the safety track record is very strong," Comella says. "We feel very confident about the procedures that we do, and we've had great success in many different indications."

According to the New England Journal of Medicine report, The Florida clinic was using adult stem cells, which circulate in various parts of the body, including in fat tissue. While those cells may someday be turn out to be useful for treating disease, none have been proven to work.

The body produces a variety of stem cells. The kind that have generated the most excitement and controversy are human embryonic stem cells, which are derived from early human embryos and can be coaxed to become any kind of cell in the body.

Scientists are also excited about iPS cells, which can be made in the laboratory by turning any cell in the body, such as skin cells, into cells that resemble embryonic stem cells.

Those are the cells that were tested by the Japanese scientists. The stem cells were converted into retinal pigment epithelium (RPE) cells, which are the cells that are destroyed by macular degeneration.

"This represents a landmark," says Daley. "It's the first time any patient has been treated with cellular derivatives of iPS cells. So it's definitely a world first."

Daley noted that the scientists only treated one of the patient's eyes in case something went wrong, to ensure remaining vision would not be threatened in the other eye.

After at least a year, no complications had occurred and the patient had not experienced any further deterioration of vision in the treated eye. While that is promising, more patients would have to be treated and followed for much longer to know whether that approach is successful, Daley says.

"Given that macular degeneration is the most frequent cause of vision loss and blindness in the elderly and our population is aging, the prevalence of macular degeneration is going up dramatically," Daley says. "So to be able to preserve or even restore sight would be a really remarkable medical advance."

Despite the potentially encouraging results with the first patient, Daley noted that the Japanese scientists decided not to treat a second patient and suspended the study. That's because they discovered worrisome genetic variations in the RPE cells they had produced for the second patient.

"They weren't certain these would cause problems for the patient, but they were restrained enough and cautious enough that they decided not to go forward," Daley says. "That's what contrasts so markedly with the approach of the second group, who treated the three patients with an unproven stem cell therapy that ended up have devastating effects on their vision."

In this case, the New England Journal of Medicine report says, patients paid $5,000 each to receive injections of solutions that supposedly contained stem cells that were obtained from fat removed from their abdomens through liposuction.

Even though the safety and effectiveness of this procedure is unknown, all three patients received injections in both eyes.

"That's what led to these horrible results," says Thomas Albini, a retina specialist at the University of Miami's Bascom Palmer Eye Institute, who helped write the report.

Before the procedure, all three women still had at least some vision. Afterwards, one woman was left completely blind while the other two were effectively blind, Albini and his colleagues reported.

The cases show that patients need to be warned that something that "sounds too good to be true may indeed be too good to be true and may even be horrible," Albini says.

Continue reading here:
3 Women Blinded By Unproven Stem Cell Treatments - NPR

IPS Cell Therapy Comments Off on 3 Women Blinded By Unproven Stem Cell Treatments – NPR | March 16th, 2017

Guiding a recent tour of a Kyoto University lab, a staff member holds up a transparent container. Inside are tiny pale spheres, no bigger than peas, floating in a clear liquid. This is cartilage, explains the guide, Hiroyuki Wadahama. It was made here from human iPS cells.

A monitor attached to a nearby microscope shows a mass of pink and purple dots. This is the stuff from which the cartilage was grown: induced pluripotent stem cells, often called iPS cells. Scientists can create these seemingly magical cells from any cell in the body by introducing four genes, in essence turning back the cellular clock to an immature, nonspecialized state. The term pluripotent refers to the fact iPS cells can be reprogrammed to become any type of cell, from skin to liver to nerve cells. In this way they act like embryonic stem cells and share their revolutionary therapeutic potentialand as such, they could eliminate the need for using and then destroying human embryos. Also, iPS cells can proliferate infinitely.

They can also give rise, however, to potentially dangerous mutations, possibly including ones that lead to cancerous tumors. Thus, iPS cells are a double-edged swordtheir great promise is tempered by risk. Another problem is the high cost of treating a patient with his or her own newly reprogrammed cells. But now Japanese researchers are trying a different approach.

When Kyoto University researcher Shinya Yamanaka announced in 2006 that his lab had created iPS cells from mouse skin cells for the first time, biologists were stunned. In 2007, along with James Thomson of the University of WisconsinMadison, Yamanaka repeated the feat with human skin cells. Many hailed the opening of an entirely new field of personalized regenerative medicine. Need new liver cells? No problem. Patients could benefit from having their own cells reprogrammed into ones that could help treat disease, potentially eliminating the prospect of immune rejection. In 2012 Yamanaka shared the Nobel Prize in Physiology or Medicine with John Gurdon for discovering that mature cells can be converted to stem cells. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy, the Nobel judges wrote. To capitalize on the discovery, Kyoto University set up the $40-million Center for iPS Cell Research and Application (CiRA), which Yamanaka directs.

A decade after the Yamanaka teams groundbreaking discoveries, however, iPS cells have retreated from the headlines; to the layperson, progress seems scant. There has only been one clinical trial involving iPS cells, and it was halted after a transplant operation on just one patienta Japanese woman in her 70s with macular degeneration, a condition that can lead to blurry vision or partial blindness. Doctors at Kobe City Medical Center General Hospital used her skin cells to grow iPS cells, which were reprogrammed into retinal cells and implanted in her eye. The treatment stopped the degeneration but the trial was halted in 2015 because genetic mutations were detected in another batch of iPS cells intended for another patient. Regulatory changes, under which the Japanese government allowed the distribution of iPS cells for clinical use, also prompted researchers to switch the study to a more efficient process of using cells from third-party donors instead of using a patients own cells. The Japanese government has a lot of incentives to considerwere developing a new science, a new technology and also a new economic market, says CiRA spokesperson Peter Karagiannis. So theres the ethical issues, but theres also money to be made. How do we balance the two?

The Kobe clinical trial had a lot riding on it. And the setback followed a major stem cell scandal in which biologist Haruko Obokata of the Riken Center for Developmental Biology was found to have falsified data in studies, published in 2014, that claimed a new method of achieving pluripotency. Then, earlier this year, Yamanaka had to apologize at a news conference after it was discovered that a reagent used to create iPS cells at CiRA was mislabeled, which could mean the wrong reagent was used. Although the mix-up is being examined, the center has halted supplies of some of its iPS cells to researchers across Japan; the error also set back by a few years a CiRA project to produce clinical-grade platelets from iPS cells.

But Yamanaka says he remains focused on the bigger picture of iPS cells and is still optimistic they can not only help researchers but may be key to transformative clinical therapies. CiRA still has a bank of tens of millions of iPS cells that have already been reset and checked for safety, so they can be used in patient applications. In terms of regenerative medicine, things have gone quicker than I expected, Yamanaka says, adding, iPS cells have exceeded expectations because of their potential for disease modeling, which allows us to elucidate unknown disease mechanisms, and drug discovery.

Those hoping for quick clinical success should remember it takes time for revolutionary treatments to go from lab bench to bedside, says Andras Nagy, a stem cell researcher at Mount Sinai Hospitals LunenfeldTanenbaum Research Institute in Toronto, who has not been directly involved in Yamanakas work. If you fully appreciate the paradigm-shifting nature of iPS cells, tremendous progress has in fact been made over the past 10 years, says Nagy, who in 2009 established a method of creating stem cells without using viruses (which had initially been used to deliver reprogramming genes into targeted cells). By comparison, penicillin was discovered as an antibiotic in 1928, but it was not available in the clinic until the early 1940s.

Researchers in Japan are meanwhile using iPS cell technology to pave the way to better drugs. For instance, CiRAs Kohei Yamamizu recently reported developing a cellular model of the bloodbrain barrier made entirely from human iPS cells. It could become a useful tool for testing drugs for brain diseases.

All eyes, however, are back on Kobe City Medical Center General Hospital, which is resuming its retina trialthis time with iPS cells from donors instead of cells from patients themselves. Using CiRAs bank of iPS cells, there are significant time and cost savingsit could be one fifth the cost of cell preparation and patient transplant or less. The initial study, with its personalized approach, reportedly cost about $875,000 for just one patient. We plan to evaluate the efficacy of transplanting the [donor] cells and consider the feasibility of using this method as a routine treatment in the future, accessible to the wider society, study co-leader Masayo Takahashi of the RIKEN Center for Developmental Biology said at a February press conference in Kobe. Her husband Jun Takahashi, a researcher at CiRA, is also planning to use donor-derived iPS cells for a clinical applicationto help treat patients with Parkinsons disease.

Nagy admits the promise of personalized cell regeneration is probably too costly for mainstream use, and he believes genomic editingin which DNA is inserted or deletedis key to safe iPS cell implants. For his part, Yamanaka is cautiously optimistic about iPS cells as a therapeutic tool.

Regenerative medicine and drug discovery are the two key applications for iPS cells, Yamanaka says. With the use of iPS cell stock, we are now able to work quicker and cheaper, so thats the challenge going forward.

See the original post here:
Waiting to Reprogram Your Cells? Don't Hold Your Breath - Scientific American

IPS Cell Therapy Comments Off on Waiting to Reprogram Your Cells? Don’t Hold Your Breath – Scientific American | March 15th, 2017

Researchers decipher how the body controls stem cells Science Daily "In the lab, we have observed the same differentiation pattern in so-called iPS cells, or induced pluripotent stem cells, which can transform into many different types of cells." This knowledge can help the researchers to improve the effectiveness of ... and more »

Read the rest here:
Researchers decipher how the body controls stem cells - Science Daily

IPS Cell Therapy Comments Off on Researchers decipher how the body controls stem cells – Science Daily | March 15th, 2017

MILPITAS, Calif.--(BUSINESS WIRE)--

Applied StemCell (ASC), a leading stem cell and genome-editing company with a goal to advance genome editing and stem cell technologies for biomedical research and clinical applications, welcomes Dr. Michele Calos as a member of the companys Scientific Advisory Board (SAB).

Dr. Michele Calos is a Professor of Genetics at the Stanford University School of Medicine, Vice President of the American Society of Gene and Cell Therapy, and has served as an Advisory Committee member for the US FDA, grant review panels for the NIH and NSF, and on numerous editorial review committees of scientific journals. She is a leader in the field of molecular genetics and has developed several novel vector systems for genetic manipulation of mammalian cells. In particular, she developed novel methods for sequence-specific integration in mammalian cells using the C31 phage integrase system. A similar integrase system was also successfully used in site-specific integration in human ES and iPS cells. For this work, Dr. Calos holds a joint patent application with Applied StemCells Chief Scientific Officer, Dr. Ruby Yanru Chen-Tsai and several other Stanford researchers. Dr. Calos pioneering work with C31 integrase also set the scientific stage for ASCs TARGATT integrase technology, which was co-developed by Dr. Chen-Tsai and Dr. Liqun Luo of Stanford University for gene modification in mouse models.

We are extremely pleased to have Dr. Calos join as a member of our scientific advisory board. With her impressive background in integrase gene modification technology and gene therapy, Dr. Calos will be an invaluable guide in furthering expansion of our genome editing platforms and our gene/cell therapy pipeline, said Ruby Yanru Chen-Tsai, Ph.D., Co-founder and Chief Scientific Officer of Applied StemCell.

Dr. Calos and her research team are currently focused on gene therapy and genome engineering for the treatment of Duchenne and Limb Girdle Muscular Dystrophies and developing further novel strategies for gene and cell therapy.

About Applied StemCell, Inc.

Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT and CRISPR/Cas9. For more information, please visit http://www.appliedstemcell.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170306005063/en/

View original post here:
Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the ... - Yahoo Finance

IPS Cell Therapy Comments Off on Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the … – Yahoo Finance | March 12th, 2017

MILPITAS, Calif.--(BUSINESS WIRE)--Applied StemCell (ASC), a leading stem cell and genome-editing company with a goal to advance genome editing and stem cell technologies for biomedical research and clinical applications, welcomes Dr. Michele Calos as a member of the companys Scientific Advisory Board (SAB).

Dr. Michele Calos is a Professor of Genetics at the Stanford University School of Medicine, Vice President of the American Society of Gene and Cell Therapy, and has served as an Advisory Committee member for the US FDA, grant review panels for the NIH and NSF, and on numerous editorial review committees of scientific journals. She is a leader in the field of molecular genetics and has developed several novel vector systems for genetic manipulation of mammalian cells. In particular, she developed novel methods for sequence-specific integration in mammalian cells using the C31 phage integrase system. A similar integrase system was also successfully used in site-specific integration in human ES and iPS cells. For this work, Dr. Calos holds a joint patent application with Applied StemCells Chief Scientific Officer, Dr. Ruby Yanru Chen-Tsai and several other Stanford researchers. Dr. Calos pioneering work with C31 integrase also set the scientific stage for ASCs TARGATT integrase technology, which was co-developed by Dr. Chen-Tsai and Dr. Liqun Luo of Stanford University for gene modification in mouse models.

We are extremely pleased to have Dr. Calos join as a member of our scientific advisory board. With her impressive background in integrase gene modification technology and gene therapy, Dr. Calos will be an invaluable guide in furthering expansion of our genome editing platforms and our gene/cell therapy pipeline, said Ruby Yanru Chen-Tsai, Ph.D., Co-founder and Chief Scientific Officer of Applied StemCell.

Dr. Calos and her research team are currently focused on gene therapy and genome engineering for the treatment of Duchenne and Limb Girdle Muscular Dystrophies and developing further novel strategies for gene and cell therapy.

About Applied StemCell, Inc.

Applied StemCell, Inc. is a leading stem cell and gene-editing company focused on the development of products and therapeutics that are enabled by its proprietary gene editing platform technologies TARGATT and CRISPR/Cas9. For more information, please visit http://www.appliedstemcell.com.

Read more from the original source:
Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the ... - Business Wire (press release)

IPS Cell Therapy Comments Off on Applied StemCell Announces the Appointment of Dr. Michele Calos, Stanford Professor and Vice President of the … – Business Wire (press release) | March 7th, 2017

"Stem cells have enormous potential for alleviating suffering for many diseases which currently have no effective therapy. The field has progressed to the clinic and it is important that this pathway is underpinned by excellent science and rigorous standards of clinical research. The journal provides an important avenue of publication in translational aspects of stem cell therapy spanning preclinical studies, clinical research and commercialization."

Timothy O'Brien,Editor-in-Chief,Stem Cell Research & Therapy

"The study of stem cells is one of the most exciting areas of contemporary biomedical research. We believe that Stem Cell Research & Therapy will act as a highly active forum for both basic and translational research into stem cell biology and therapies. Specifically, by developing this forum for cutting edge research, we hope that Stem Cell Research & Therapy will play a significant role in bringing together the critical information to synergize stem cell science with stem cell therapies."

Rocky S Tuan,Editor-in-Chief,Stem Cell Research & Therapy

Read more from the original source:
Stem Cell Research & Therapy | Home page

IPS Cell Therapy Comments Off on Stem Cell Research & Therapy | Home page | March 6th, 2017

event

Date: 14 June 2017 - 17 June 2017

Location: Boston Convention and Exhibition Center 415 Summer Street Boston 02210 United States

Website: ISSCR2017.org

Email: [emailprotected]

Telephone: +1 224-592-5700

The International Society for Stem Cell Research (ISSCR) 2017 annual meeting will be held 14-17 June in Boston, Mass., U.S., at the Boston Convention and Exhibition Center. The meeting brings together 4000 stem cell researchers and clinicians from around the world to share the latest developments in stem cell research and regenerative medicine. In a series of lectures, workshops, poster presentations, and a dynamic exhibition floor, researchers focus on recent findings, technological advances, trends, and innovations that are realizing progress in using stem cells in the discovery and validation of novel treatments.

In 2017, the ISSCR is expanding its translational and clinical programming with two half-day, pre-meeting educational sessions geared toward bringing new therapies to the clinic. The Workshop on Clinical Translation (WCT) and the Clinical Advances in Stem Cell Research (CASC) programs are designed for scientists and physicians interested in learning more about the process of developing stem cell-based therapies and advances in stem cell applications in the clinic.

The Presidential Symposium recognizes a decade of progress in iPS cell research and application with a distinguished lineup of speakers including Shinya Yamanaka, discoverer of iPSCs. Additional plenary presentations include distinguished speakers from around the world focusing on organoids and organogenesis, the making of tissues and organs; stem cells and cancer; chromatin and RNA biology; stress, senescence and aging; tissue regeneration and homeostasis; and the frontiers of cell therapy.

Concurrent sessions feature new and innovative developments across the breadth of the field, and incorporate more than 100 abstract-selected speakers. Disease modelling, tissue engineering, stem cell niches, epigenetics, hematopoietic stem cells, and gene modification and gene editing are just a few of the 28 topic areas presented.

Other meeting offerings include career development sessions and networking opportunities. A full listing of the ISSCR 2017 meeting programming can be found at ISSCR2017.org.

Map

42.3461949 -71.04563680000001

Go here to read the rest:
ISSCR 2017 - Drug Target Review - Drug Target Review

IPS Cell Therapy Comments Off on ISSCR 2017 – Drug Target Review – Drug Target Review | March 2nd, 2017

Scientist Juan Carlos Izpisua Belmonte from the Salk Institute in La Jolla, California, claims that the aging process may reversible: Our study shows that aging may not have to proceed in one single direction. With careful modulation, aging might be reversed.

Izpisua Belmonte attests that he implemented a new form of gene therapy on mice that were given a genetic disorder called progeria. After six weeks of treatment, the animals looked youngerand not only that, they had straighter spines, better cardiovascular health, healed more quickly when injured and actually lived longer.

How Its Done The rejuvenating treatment performed on the mice manipulates adult cells, such as skin cells, and turns them back into powerful stem cells (similar to what is seen in embryos). These powerhouses are referred to as induced pluripotent stem (iPS) cells and have the ability to multiply and transform into any cell type in the body; in fact, in trial tests, Izpisua Belmonte says iPS cells are being designed to provide organs and limbs for patients. He claims that his latest study is the first to show that the same technique can be used on other cells to rewind the clock and make them look younger. Izpisua Belmonte explains, The treatment involved intermittently switching on the same four genes that are used to turn skin cells into iPS cells. The mice were genetically engineered in such a way that the four genes could be artificially switched on when the mice were exposed to a chemical in their drinking water.

What This Means: This finding at the Salk Institute suggests that aging may not have to proceed in one directionin fact, Izpisua Belmonte states that it may actually be reversible. Although tests have not been conducted on humans yet, he predicts that applications via creams or injections are a decade away.

This rejuvenating treatment may not lead to immortality, but due to a growing body of evidence, scientists at the Salk Institute theorize that aging is driven by an internal genetic clock that actively causes our body to enter a state of decline. In developing this technology, it is hoped that future treatments designed will slow the ticking of this internal clock and ultimately increase life expectancy.

Whats the Catch? Dr. Sidney Chiu, a 5th year resident at the University of Toronto, thinks this information should be taken with a grain of salt: The findings are promising, but nowhere near ready for the front lines of healthcare. These experiments were done in highly controlled settings on genetically modified mice. If this finding were true, it would be worthy of a Nobel Prize because it would be akin to uncovering the Holy Grail. Chiu elaborates, If you can induce iPS cells, you have the basic building blocks to regenerate anything in the body. But this is far beyond any current medical science we have.

There are also numerous issues to address concerning the study: firstly, the mice are bred in labs for these types of tests, so the variables are controlled from the outset to attain desired results. Chiu adds, In the real world, you cannot turn specific genes on and off using treated water on mice in the wild, let alone humans. There isnt one specific gene for aging; I would be cautious about this scientists claims that isolating merely four could unlock the key to anti-aging. Even if we were just talking about reviving skin tissue, if his findings were true, it would be a breakthrough.

Chiu says that while it is technically possible to alter genetic material when humans are in an embryonic state, that wasnt done here (gene editing research in human embryos is currently allowed in Sweden China, and the United Kingdom. The United States doesnt currently have any legal prohibitions against it).

But its not to say that all of this is in the realm of science fiction; Chiu offers knowledge of research being conducted specifically for telomeres and their relationship to aging. Think of telomeres as the plastic caps that protect your shoelaces from fraying. The laces would be our chromosomes, the recipe for making a living thing. In fact, telomeres have an important role; they protect genetic material from damage that could otherwise lead to diseases or cell death. But because the number of cell divisions in telomeres is finite, once they become shorter (in length) and can no longer reproduce, it causes tissues to degenerate and eventually die. It is theorized that this process may contribute to the human aging process. So scientists are trying to find ways to extend the length of telomeres.

Izpisua Belmonte says that chemical approaches (via creams or injections) might be in human clinical trials to rejuvenate skin, bones and muscle within the next decade. However, from his perspective as a frontline healthcare worker, Chiu believes that we may just have to wait a bit longer than that before such innovations are accessible to everyone.

Main Photo by Thomas Rydberg, CC-BY

Tiffany Leigh is a Toronto-based food, travel, and science writer.

Read more:
What's the Catch: The Fountain of Youth - Paste Magazine

IPS Cell Therapy Comments Off on What’s the Catch: The Fountain of Youth – Paste Magazine | February 21st, 2017

Slacking off in ALS? Mutant SOD1 may partially close the SLACK ion channel resulting in increased excitability in some neurons (Zhang et al., 2017).[Image: NIGMS.]

Increased activity in the motor cortex of the brain may occur in most forms of ALS (see September 2015 news). But whether this hyperexcitability contributes to the disease remains an open question.

Now, researchers at Yale University make the case that ALS-linked mutant SOD1 may downregulate a key sodium-gated potassium ion channel, known as SLACK, through an apoptosis signal-regulatingkinase1 (ASK1)-based mechanism (Zhang et al., 2017).

The findings may help explain how motor neuron hyperexcitability occurs in ALS. These changes in excitability may contribute to disease pathogenesis and may underlie fasciculations, one of the earliest clinical manifestations of the disease.

The question is whether this pathway is the primary way that SOD1 mutations cause disease, said Steve Vucic of the University of Sydney, who was not involved in the study. If so, [there] is a tremendous opportunity for developing treatments against these kinase pathways.

The study is published on January 24 in the Journal of Neuroscience.

Excitement builds

Neuronal hyperexcitability emerged in recent years as an early and potentially unifying stepin ALS, due to its detection in a number of sporadic and genetic forms. While the evidence is still not yet conclusive, some studies suggest that this prolonged excitation can lead to toxicity, strengthening the case that these changes in excitability may contribute to the disease (Fritz et al., 2013; Hadzipasic et al., 2014).

How hyperexcitability occurs in ALS remains unclear. But a growing number of studies suggest that mutant SOD1 may be involved, at least in some cases of the disease (Wainger et al., 2014; van Zundert et al., 2008).

Researchers at Yale University, led by Leonard Kaczmarek and Arthur Horwich, wondered whether mutant SOD1 could trigger hyperexcitability in motor neurons by downregulating a key membrane-bound ion channel called SLACK (sequence like a calcium-activated K channel), also known as KCNT1 or KNa1.1.

SLACK is a key regulator of excitability that helps neuronsreturn to the resting state upon firing. Its widely expressed in the CNS and its dysfunction has also been implicated in neurological diseases including Fragile X and epilepsy (Barcia et al., 2012; Heron et al., 2012; Martin et al., 2014).

Hyperexcitability in the bag. Researchers use sea slug bag cell neurons to study underlying hyperexcitability mechanisms. [Image: Kabir et al., 2001 under a CC-BY-NC-SA license.]

To investigate this question, first co-authors Yalan Zhang and Weiming Ni turned to the neuronalmodel system, the sea slug Aplysia. The system gained recognition in the 1960s for its role in providing Eric Kandel Nobel Prize-winning insights into learning and memory formation.

The approachinvolves the manipulation and study of bag cell neurons, very large neuroendocrine cells in the sea slugs abdomen that control egg laying. The really big advantage is that, because of their size, you can inject materials into them and then use a very fine microelectrode to record changes in excitability, all without any disturbance of the cytoplasm, Kaczmarek said.

The researchers compared the activity of potassium channels in bag cell neurons in the presence or absence of wild-type or mutant SOD1, including soluble oligomers of increasing size. They found that SOD1 or mutant SOD1 G85R monomers had no effect. But when they injected SOD1 G85R oligomers, they observed a reduction in outward potassium currents by 20-30%. This drop occured within 10 minutes and increased with larger oligomer size.

Whats more, SOD1 G85R oligomers increased excitability of these neurons. Injection of these soluble 300 kDa protein complexes decreased the neurons resting membrane potential and increased its susceptibility to firing in response to applied stimuli, they found.

Further experiments identified the SLACK channel as the one most likely to have been affected by mutant SOD1, because neurons pretreated with siRNA against SLACK mitigated the effect of these protein complexes in these neurons.

Together, the results suggest that soluble mutant SOD1 oligomericcomplexes may lead to hyperexcitability due to partial closure of SLACK, a key sodium-gated potassium channel that helps neurons return to their resting state upon firing.

ASK1ing for trouble

How could mutant SOD1 downregulateSLACK? The researchers suspected that these effects may be triggered by ASK1, a key kinase that has been previously implicated in the destruction of motor neurons in the disease (Raoul et al., 2002).

ASK1 has been shown to mediate key effects of mutant SOD1 in mouse models of the disease including ER stress and disruption of axonal transport (Lee et al., 2016; Song et al., 2013). In addition, inhibitingthis pathway appears to extend the survival of a SOD1 G93A mouse model of the disease (Fujisawa, et al. 2016).

To investigate this possibility, the researchers blocked ASK1 signaling and determined the impact of SOD1 oligomeric complexes on potassium channel activity. They found that the suppression of outward potassium current could be abolished by pre-treatment with an inhibitor of the apoptosis signaling regulating kinase ASK1. Similar effects were achieved with an inhibitor of one of ASK1s downstream targets, JNK.

The results, Kaczmarek said, suggest that mutant SOD1 oligomericcomplexessuppressSLACK channels in neurons through a ASK1-based mechanism, causing hyperexcitability.

Its an attractive idea, says Massachusetts General Hospitals Brian Wainger, who was not involved in the study. The findings may provide a potentially direct mechanistic connection between mutant SOD1 and motor neuron hyperexcitability in ALS.

Mind your Potassium and KCNQs. Researchers are evaluating Kv 7.2 potassium channel activators including retigabine (orange) in hopes to reduce hyperexcitability in people with the disease. More specific channel modulators are being developed. One such activator, AUT00063, is being evaluated at the phase 2a stage by the London startup Autifony Therapeutics to treat hearing disorders. [Miceli et al., 2011 under CC BY 4.0 license.]

But a change in excitability may not be the only or even the most important consequence of SLACK down regulation, according to Kaczmarek. SLACK may act as an activity sensor, providing a direct link between neuronal firing and protein synthesis.

His teamhas previously shown that SLACK channel activity plays a role in synaptic development, through its ability to regulateactivity-dependent protein synthesis (Brown et al., 2010; Zhang et al., 2012). When you precipitate the channel from mammalian brain, it pulls down several messenger RNAs, he pointed out, and mutations that cause channel overactivity are associated with epilepsy (Barcia et al., 2012; Kim et al., 2015).

In fact, Kaczmarek added, it may not be the hyperexcitability of motor neurons that is toxic in ALS, but rather its proposed (but not yet tested) consequences on protein synthesis. A rapid change in the activity of these channels, as we saw here, is likely going to alter protein synthesis, and that can produce much longer-lasting effects, potentially more consistent with a late-onset disease.

This was an extremely elegant study, and an ingenious way to approach the issue of hyperexcitability, said Steve Vucic, who, in collaboration with University of Sydneys Matthew Kiernan in Australia helped identify these neuronal changes as an early sign of ALS in people with the disease. The goal now will be to see if this same pathway is affected in the mammalian models, or in human ALS iPS cells.

Brian Wainger agrees. The key questions, according to Wainger, are whether these findings hold up in mammalian models, and whether these findings can be generalized to other forms of the disease.

Searching for ALS-linked gene variants in SLACK or related ion channels might also provide insight into its relevance for the human disease, added Vucic.

Approaching the clinic

Hyperexcitability is clearly a clinical feature of many forms of familial and sporadic ALS, explains Wainger. Thats why it is attractive as a convergent mechanism for many forms of ALS. But one of the challenges is to determine to what extent an increase in firing is relevant for disease pathogenesis, rather than, as some argue, being a compensatory mechanism. Directly modulating excitability is one of the clearest ways of answering that question directly, he added.

If motor neuron hyperexcitabilitydoes hold up as a driver of disease, however, it may be a good target for therapy, according to Kaczmarek. I see this as very much a therapeutic possibility.

The reason is because opening up these potassium ion channels may help motor neurons in people with ALS return to their resting state and thereby, reduce hyperexcitability in the disease.

Finding magneto. Researchers are using transcranial magnetic stimulation to evaluate in part whether mexiletine and retigabine reduce hyperexcitability in people with the disease.[Image: NIH].

Kaczmareks team is now hoping to do just that by developing a SLACK activator. The project is ongoing.

In the meantime, clinicians are aiming to reduce hyperexcitability in people with ALS by repurposing existing medicines in hopes to treat the disease. Brian Wainger is leading an effort to determine whether the epilepsy drug retigabine may be helpful in ALS. The drug, identified by Wainger as a potential treatment while in the laboratory of Kevin Eggan, may help normalize the activity of motor neurons by opening up Kv7 potassium channels in people with the disease (see April 2016 news; ; Wainger et al., 2014).

Across the US, the University of Washingtons Michael Weiss is taking a different approach. He is evaluating whether mexiletine, a sodium channel blocker, may reduce hyperexcitability in people with the disease (see March 2016 news). Both strategies are currently at the phase 2 stage.

In a disease that has a selective neuronal vulnerability like ALS, says Wainger, I think it is likely that the electrophysiological properties of the neuron are going to be related to the degenerative nature of the disease. So normalizing those properties may have a good chance of being helpful.

References

Zhang Y, Ni W, Horwich AL, Kaczmarek LK. AnALS-associatedmutantSOD1rapidlysuppressesKCNT1 (Slack) Na+-activated K+ channels in Aplysia neurons. J Neurosci. 2017 Jan 24. pii: 3102-16. [PubMed]

Fritz E, Izaurieta P, Weiss A, Mir FR, Rojas P, Gonzalez D, Rojas F, Brown RH Jr, Madrid R, van Zundert B. MutantSOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. J Neurophysiol. 2013 Jun;109(11):2803-14. 2013 Mar 13. [PubMed].

Hadzipasic M, Tahvildari B, Nagy M, Bian M, Horwich AL, McCormick DA. Selective degeneration of a physiological subtype of spinal motor neuron in mice with SOD1-linked ALS. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16883-8. [PubMed].

Wainger BJ, Kiskinis E, Mellin C, Wiskow O, Han SS, Sandoe J, Perez NP, Williams LA, Lee S, Boulting G, Berry JD, Brown RH Jr, Cudkowicz ME, Bean BP, Eggan K, Woolf CJ.Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014 Apr 10;7(1):1-11.[PubMed]

van Zundert B, Peuscher MH, Hynynen M, Chen A, Neve RL, Brown RH Jr, Constantine-Paton M, Bellingham MC. Neonatal neuronal circuitry shows hyperexcitable disturbance in a mouse model of the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Neurosci.2008 Oct 22;28(43):10864-74. [PubMed].

Barcia G, Fleming MR, Deligniere A, Gazula VR, Brown MR, Langouet M, Chen H, Kronengold J, Abhyankar A, Cilio R, Nitschke P, Kaminska A, Boddaert N, Casanova JL, Desguerre I, Munnich A, Dulac O, Kaczmarek LK, Colleaux L, Nabbout R. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012 Nov;44(11):1255-9. [PubMed].

Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, Licchetta L, Oliver KL, Mazarib A, Afawi Z, Korczyn A, Plazzi G, Petrou S, Berkovic SF, Scheffer IE, Dibbens LM. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 2012 Nov;44(11):1188-90. [PubMed].

Martin HC, Kim GE, Pagnamenta AT, Murakami Y, Carvill GL, Meyer E, Copley RR, Rimmer A, Barcia G, Fleming MR, Kronengold J, Brown MR, Hudspith KA, Broxholme J, Kanapin A, Cazier JB, Kinoshita T, Nabbout R; WGS500 Consortium., Bentley D, McVean G, Heavin S, Zaiwalla Z, McShane T, Mefford HC, Shears D, Stewart H, Kurian MA, Scheffer IE, Blair E, Donnelly P, Kaczmarek LK, Taylor JC. Clinical whole-genome sequencing in severe early-onset epilepsy reveals new genes and improves molecular diagnosis. Hum Mol Genet. 2014 Jun 15;23(12):3200-11. [PubMed].

Raoul C, Estvez AG, Nishimune H, Cleveland DW, deLapeyrire O, Henderson CE, Haase G, Pettmann B. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron. 2002 Sep 12;35(6):1067-83. [PubMed].

LeeS, Shang Y, Redmond SA, Urisman A, Tang AA, Li KH, Burlingame AL, Pak RA, Jovii A, Gitler AD, Wang J, Gray NS, Seeley WW, Siddique T, Bigio EH,LeeVM, Trojanowski JQ, Chan JR, Huang EJ. Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron. 2016 Jul 6;91(1):41-55. [PubMed].

Song Y, Nagy M, Ni W, Tyagi NK, Fenton WA, Lpez-Girldez F, Overton JD, Horwich AL, Brady ST. Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5428-33. [PubMed].

Fujisawa T, Takahashi M, Tsukamoto Y, Yamaguchi N, Nakoji M, Endo M, Kodaira H, Hayashi Y, Nishitoh H, Naguro I, Homma K, Ichijo H. The ASK1-specific inhibitors K811 and K812 prolong survival in a mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2016 Jan 15;25(2):245-53. [PubMed].

Brown MR, Kronengold J, Gazula VR, Chen Y, Strumbos JG, Sigworth FJ, Navaratnam D, Kaczmarek LK. Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack. Nat Neurosci. 2010 Jul;13(7):819-21. [PubMed].

Zhang Y, Brown MR, Hyland C, Chen Y, Kronengold J, Fleming MR, Kohn AB, Moroz LL, Kaczmarek LK. Regulation of neuronal excitability by interaction of fragile X mental retardation protein with slack potassium channels. J Neurosci. 2012 Oct 31;32(44):15318-27. [PubMed].

Kim GE, Kronengold J, Barcia G, Quraishi IH, Martin HC, Blair E, Taylor JC, Dulac O, Colleaux L, Nabbout R, Kaczmarek LK. Human slack potassium channel mutations increase positive cooperativity between individual channels. Cell Rep. 2014 Dec 11;9(5):1661-72. [PubMed].

disease-als hyperexcitability mexiletine retigabine SOD1 topic-preclinical topic-researchmodels

See the article here:
A key ion channel may SLACK off in ALS - ALS Research Forum

IPS Cell Therapy Comments Off on A key ion channel may SLACK off in ALS – ALS Research Forum | February 20th, 2017

n}"Iu'.-[@$(~I)/NNbr.PBZ0R W.?ry3G|6EABWfShU+3W31@L-*3vf ~nQr1AsiP*T Qhn8EyR-^B_V|,9n )GI^chn0ZZvu9Ri}Z $(_*](u"&E1.LgERi#A,lq=&giZpx6f,dq08qsJ)rsFhW?sYL?OCL?X%81nUua*UjVMw:S*zL"BxLM"x}Y%m~fRRM)8#Y%cQHF#Y,P_g |.e&( 2A"d>WU23%0T'( g,,Ms3#t,QIf2%,TE2 , |[N,)!a7<0 2?M 4q4H)dc2 ,J y1F,J_B6dd4%OX3wh$SdcF~j4 f$gnd$~N6W-+r?+XR2? DI4Bd~4M)!%/GZ}u1x@D@~z&Puc/~%%D&1<"$ hQeE[Q28G0 #J,(u3"y@58p]0fuOeB_-gGhI8)Qv!1*y@O|I(,d!ei*'i&O;%dn:49qf %Ju{ 3pmV29_ 0y{*ZR}jT;2}2lekF;*S21u&Nm*Xe9-< P-A+?g`B7JOj}tu,$o!8UpB#WmYMU.l1)}SsXftR?s:LSpdy$icRtclZCPun A.4,e8.=V2Tk@5%UT`u7~cQC7RC'wCj.GG|$NM &2o&'^MO7t; Rn]2lrdup]wzwkG{Eyq*94r:_4@tS@ml1<-Z*o#y8 Wu}[7dj7GL"_5Iup*X9toEMD[Yo8+ `|$Pd,ia/CR<"@ K"9CHJ}]P(=Y $#fXAfI#WqL2F'(TSSxx"<0ETwYVq)ZL Eak) 2xXb:D<`!bhDFIH>^C;2hy8X&M3SzL(X4=GlIig.!~Dr6#}kpbnds{>2J%E,5 ."[m.' 4]_`sn? v 8]FR.k]@m}q{x`Gx^D"(r?d u[vd]7fn?k;Y1WZc$#9]VP$bqz/~:3m^FpO !UWTPC{ Bcz&u.X4h'uj%Gc4fd 0&WRY"YSP7Pd=u<{5K)?n{IbPa/Q|Ay90'7wzF,Col~q8LxYcU"Fk.x*7ZmCm%8z%DLq / hDW@Y$:]e&Ha{'zmj &iW(@-/JoX`=2DH/DT5E0/CLP^_XAK;6)f_]KO0+*bEBM{/mT[ jLGY@i<~M<36l"yM[z!lf)>W.qiYH;M :V0Oqs!k:%_}Z7k]% dB!N:Fj|o jm8P{+u O !t%Pih/] @8i*I+yf^QbS58V;NXoV(l*P<`jGl.jf@G -O^rSO:X|*Gs77UN!g}%^f'vHC'$cXL0>XqZCA|$+x-`UNy:ms -25p'mCU}LGVMi4'"`2;n/Jh6h/u!yXIXA FKf,"Y}n}"E|SO/Sj?@io:Xc4A7(h.'nha5wq3iT@-Q{|1'p1x4RfFZ"Or-DZU+= !+X018=~chAn",f;Y&y{r|[M!XAm3 J}1AQZ4]]7/cBKEmD{6OAw8<<"!oh~nbwO7n:Zwl.|.XIv"6KY]o>yU_"-"RMr0^ Ktp)ex+Q >&k(SH@d5Gy%,jB*!>}F)bh_ky>_g.&~9gOiG$|tXA<]j09A`Bz;+6)#j-q>ty5l\tS#A]{G;|>m,{>K|^un76A3LK>4|+2xCZy!d[q8GJcxoM9M]_S$nH{l8TTUxV8WWXCSwkBk@g#^O}R)KDPHo43Ao2)8}I I}G=*/dV)'fV,/ ]Kj@.`a?cv}q)8'R(DFIDIL43#Nd3c8I83wt8B!$I3A=w:NfMMz tr{sH `!W6/_FtG*HJ2[Z+l@/8$z'w/.)1~x}{O},U"wxBT,)"Iwv&s n*]Y3f_dagr}CJI7m)rgZXK{o;/oRc*HH{Ox rpIcetB@p>ggS$|O0^q-7/7L|GW9rB`08v|O@9Uq,Jj]QfiGlgjxT+I9g ~`J/HrBkS=+J{Xd`aN#2[YT,n5w"i$f IF 8hEiPUF&eLw;@Ici5Ck2k81nQ$BMb/N<"9*Z Nq"`R5_f~/VavRq)=(Z]KoD+88qA@hHnd'`,aU{ydAVe~UWG?==r7N{P|Vbh$vw*Ov C]bKKFOEo`R|s}rsYTrA@twa*?i~wf|/wW,Yl IYN=1ND.|tc]Xkx!= >_}w1Zi:1kC;fG|cy SIKw(w{5_7j_8h_WPBt}tz} 6igh/*1TM=gjka[-3 }Yya9u>=NL5&t;b71m+xx=vpyy?P[a.&aF<)__mnOL[TB[kOW!v:r7M[kq_4qH1FSzY_1)Y&sy6yFRgy{; $7#&KTL]H/|(}Z"s,{Rl.n}xcf&9*9D{q{DN]]W0HqAB/{YHsZfW/7~W[f2q6nD/_w6/$iFnt9'riXF"Mrpc9&[ecI>#:G_N, v= y-N< Y)dw,e&YqM~tQ"cn/;.>6Y'BXHQ1.H#XmlB^RLM3Clw`#R[+8H"8,y +|l`${ EfXdTlFtsB{4,Z`cp4Mb'+fp @*ND)Sm??cT8R#2wV1k<>3 9xy qI DxW.K-~-%VtG&05XNz+W 5>'"T =1+f?pbB3*;0 5Z g 'jrnob }@wDk{#PN,3N$>4DFG;6*LUe]bBd2UNU UC3[6p%nY#@Q]D5:`dQ`'uc"7Nnifc=DZSHaE@yu mA%1R;CuIXt$V"[a}1./PU9(s!,vX$/(Aa%YLFOP pc6S{MHKx|9@,7e3H7:M7K^N!9Er6DjqjS7^T.Bz~,)qJ/:z?NSX:Qu@ akFL(,'$B{_!hN;qx )T8jvX,x?|0M(*I+AER`,lP#g(cP"$A@7tkTf`"G(Tq2j C' rNs}4Rs%` 7KH2X'P*AaC-Gx&6P`/,29-k00rFOtfzDbLQ^(F:NzG!BMS>0 hL`Rv#;m#HS_// Efg_DH9UK18^da(/tu:dh}H@n[M=_Ag 3X]HMKS EP&3c5LrLXT0i=Qz{`yfY iHHZ9< @qJi m'|`~)uWQ/~9?w:7JJ"#U];?/M"-7w')o=@VC4k#%mC-}}1(;I!.eF3KuJPfs8qn^uk1[7f5z(?m\Ch:?GykWU.=V~cyo7eq?%}R2}"]RzYjo+enQk`y&LfiB|! {^jh7j>uQ=^x; >% TlfcmX'5Bx|`!4j5AQV#4a($`*iQ/%][$s4.wV]"Ic[!8wk2_;H5]i9yGYjI5Lfu ^/z. oxLAMBPu=X"t]]C!{Kd{E*<)U?MoqG~N4W75=N,_|~H+>_>"Sj[CuIIa$;wW2>M- 'pQFZQKEl9Ut qX?H3Su `= (qY b{st$9EK$cnL1J7-YjM>{bT-5i+R0NfoZv ,Iv$h&jn"Ar2 `|B$.bPR94GfEO(oJQt%R&6NRZ@W^*h)m"HgJg)A&Q8hCo8n1`lZyS|'hTcV]]2~btE&4OGK.kC; $,l`Es!nM,I51P ek"[v+^4l.c5Z9ZP P!{?MnX H]un|{[lo 1z?,Qs 2C}k9|5D<>]FUw:5=*i?s/nIE% z5vhh,4[qj;I`4+3d<5(Df29 7YOG$zW:z{lcgQe;h3@g9S@GETq y"Y"{SS!<-Sr=U.l,wn,"vJIT=R6"#0''m2Q@6?y$xEJfB @%W!E:e0rd&Xj r'"=a ;$11w> <+j-_G+;|PDp8gq ,O,dpxf) +li($;p,{h8S22Nl2'6&/PEqOVjbM0.-fbIJFeLKh*_>@)0R:ngDPRuH2.T9vA7gTv )V K{fe1+UeX)TaV[VtKTs6OT*);eqrvdf0fh*ZTUVI4+kI;aTJ/~K_ =MFMS_9xBr1?/*_?DN 1$fN&O.M>A9eOV_W+^:XS/~ZV}`<~_jA[i ]EqifU3y?O+k./z&1mu[<5X._="rHYQTHw*{a~_PtsDU7PISpezn $ &?*ec&r3P-.bvA6Xd(' BuJT3< +.iQ(~a`1xZ2jkv3P2ZjME2u9`=E8$tQW P`qW.x`dX>L1!~%6n;M{0-9z?hN_F^M:.:y!d B@i-Tz=(h*uLm*N8L5Q}3;t& <.IT5T<]._o ^BzMF;+&ei$23X2:|TJJUpSc'*$ Vu943<$ v}mlIvU8@=,^SIbVj-SSUMK3PuwZJ+&W=L!GkvupF|**/9X6NF"xtUIiA:2`/OJfthoVB'u DaF+iF3.ft6|>WV|HnY1}!!+aFJ>bU'@ox1y'jZ2=LhDftv!OvYu=3Zr)6_E/@D |};OETe{eFbCPl"n$.iK7z69V6F6R,tl%yDYhECU[(FDb]l$yPt,YQ.'MAB>ltF:TtJn!ka>y^hT"]NP:khuFm?XyZ27oKr5o`4>FW%xs jPc"#6WnDA ObN9jaD/;ooa2|2*(OS6!WUNY`&CWUP|+$_A6XYQ%.fSm']"|>A4d7FL]T,G?d0y++2H3H0l` BKXhO*Qp-TZ[7mo3Q""8kF"e')L-YTQyzq{*4n wE+'9G_Vq B1Hk]2S=+*S)?~ p$/|-1B. 9}=*!6=pHoDdE5!MT_KXF0q[Bg31p>hwuPX5X>zp PMy()T"lLzRkJH}0)W+WZ F1D]HW0'xU5Z @,onoDmP:*7TL.Je<@ `1z57b^TGWMe k8'#?fCXu'5KIFED__WeIsolglC,gNaQ4> 8{|viq>Q>2f1t_b}?oy{6.}`/cuW=hp),& C982dmk8Ct!-a]1_mv)x )j1 #nB&k_vVs^{3g tJ$v}2)BX 7 :*kq5Ulufut}6+`%SX8rQ'<;sm|mAvO 7I*t&MSa0UGqv"i:8Vb PZOk VAM8hR+W+tLj?DH3G)mzmAuSld ,QuUc,cZHB4x>=pZxr{1''Q{$xRL+lhgD;JW{%UT.V[32w0N m8"#"6R2}5N=?Qe6c#sYr6J_i9*-rum:/vFIs^]V;{_d$s#j2Mq}s1 |$XblJVUqw~@80"(df `Pd`-YOz Kx?]K6 /@CW59}MYTe'D@C23 #[yl`[C"F8B^P"-U||`8IgiY| RoKNl"o:LQ$+qVy - ^Nv3ydq6>(_u=vOa)1U66=FYH@bM1v?Q-2<3Tkeh-*B#]$4 &'|Xhl?)!V96@k*L4X1Uh{q; S'k_NY8/zPKs*\f*P1#IZ}K@"jsuD 26Wl*DQ|DCN@="N>jQ|Y[ z-V8;9{:U-zB&a9"mD>6GF3Q3n~b,|zImE@(.o*{d%Ega{4W1(F-sx7&VI9j !1=$ 0f8%}u0/-SX#-lR!PdUd8GyKX2*'iZ(hQK90WTGq!E1B^LKJ[B}C (X-THfp}I`n}e4 p2T>]rBlD~0),BNJ'U!!&eIwC#es /FWQ 2xH857G@KFBs=_i!o Ff^Q_1)'$^'V.^iq,;mw59mAg4bDDO`1vtPVhV]Q68m{]a,MJ` COzQTMR#>BKT-~8tI$G'P|>Z`:^"(!B1A)-0e*oUYzRfFHX`Ew ?:*G!9:V_qoza,?Co@1+YPSmQO~g;UHJyv%7xSFUg5%*ub& 8888)rP`G:E5Oo:h3rI gg;!dfyg@XbFnW}5J{NNZqxGPSAhKvYn>ZUI6;rauicwxU,rCAuAefi HiJ%08 P`7UMZ7S51[.tT&VAPjex *"qu~ [qG0 @kW?^Fy7iO]@t>Y[7=#}g `2Dme.G=NE&DU5Sinh@ac)V9Ad iNv2FCvjN93ln%+`8/)$];/_WF:5^[!CL2=sj@ B@:%71HL).MK^chJZ+#Fb;t`7SFj Cb#h#:q&+Z!f~ {4@v h^6+PlS;,.'Lf *^Pbt-<_Z(1~Rx<&a*x=6f2p_=GVC#i ~=#,C-bN9$ujS{^OSvEr%9h.Ypl<6T`'{%e,X56WPr@%}_3oe 1sJQ+myq'W9WDhP0{MNW~f1rU;J_,px G>mT~59roH3=;VdV7H =4[6g[htcH!l@`zL8^raummY}#o4O Fk#aMWrxJ+nuBP7`V2 !cI y}*!PDQ8+)y@``~;_M(,X]]f%X~V!]>l#>ObT1+ [p9,Qu~Fu_>nr}g3 q}U7)VE;3-b?3;C}3wT)qsri wz+d8P< %RDtk4$qY% XtAwwZ~*&5{41$k:!2%){V .{EpLA>0?sB_$m^{k_S$OvQWOPOyA'2'M s8ZUxJ2A_$=.mbj9ao}9}ZgndyrRjXGq{%ax ItR*4A Qf_76 ~{(H29l$Mz<-r*<(?f Fyugu~)89xHq_ZB@x8`RG;%GbSEg6i"SA_-&S_#WU;WaZe$lv>k[Y[|"o86Ni|[&G;V=}Rd245oB|R37] z6m;9v*/-;%yRLAs!u!bT[PF0 T;{ZwrX-**EVm" '3:j+/;JVS,#l3BDnT?vpC~ns3jviXaxnQO_lPmyo] hLOeM]ZM3FG97ekD5B `JF(p4jUy% H32jeWy>ne;kbCtG,)#H3H'h}UxA^KL';ZllNJh$Z:+::/Km+C dl*V)sa7+i&0?FelTMVo_FAwc4"zm"Dlj-]78e4"h,dy@?7o=k[?9oG=}7}?9eHDDrH : lmfO$`HasmT130Ma,*sD:=-cc"v0<|D`.`4rhpWb %&I! ] lH;3a(Kshtp9ASe.DKsUYn?S>m1

$F4m:s lTt+3}!YH6p4-eBv)l%L G!Cifm:!6!@@ULV^Tojx7eHu4M|]EM'R,+J& er:;9}"QU_c29Cf[RX?$t&M-+#' j'Nnu3i+cS"'52ayEZlSxSR>l:>/#TtuuUU?);sflKScU&2MJ#'(;w2 yEH3_ vKb(hZ~aM>#}-7HnrFpFF1 k79$dT TwzA/,2fyA3P}EFpdf6qu|nqqJOv9~UE1*_YC% @Z8!1m qan*2Ra+O)/oq~KLSuYaj1!_MLP~- %f!c v2Ss9m]~x }obnt4pO.6qmT,$Z~0aPz($s3`th=* J5Dg6nocay[=p"?L3zKt <0%q?h!mC#G+Mr^oVv$KE^H{|UW5Z5pY b-e4}h0=N$+5R3W)3D'/UE=#JV(Z4a!BoK&3xN>c%#k# 2g~ `cTm 2J"!l9"r<8HJP!nL%)u{{dk:O|>7hlYvL/T,B#8*g)*9lz0@q@o:+c'"7 aVF}K[bzSPFwtT!ll:"dr.On#axQ9}M9t2/nFX;e2lqVp"5,cRzohH25^ U ^: yZ MAq,ii]DZ{rFgN?BH3BRLZ-N3PqwTgADw>wThYoJK[CJ^MYE]57)Y( 1/dNm5qBVk|yI>5he; y_NNaKPiiN@(^!YIZV_x43- A@XIAxu#~tY)FeTwT[c>Ve9af8gF76z[P4-+)9FAB9 Ro*k;TMFcKz>aX R?2l=?K{pbh`bG_yF:xgS - {?A@cF3y >DX/f`fCCV*F1Y+B/8U*X/~%Q]/hz` Hj"~2gun-H+W"=wPM}=L]Y*J^@:i,~df?K-< I)}@0A }n+Fh1r^|D_O>>m1Qirh5.=ltMe!)IJlDAz"r-<,uhQ|ThMh6y,5Om;hK!h>T[Pv%U)S]LJ2dmnk[R?BY@Ed{jl v`]oz{4ntn&~;/kQpu>Kw@#[u oy Lt;CWqUF[ F ~&E}0)`^ *"n3q.Cp1csR;=EQ1o<#KS8hv&&tU8KU b-K`7R'O uKW5p_2MpvclnC7z8+($ N* yD[bjq >pYO#Ob{JA~kFe1S'by"lNz9%T.jPO0eIv.bN$S!>dr&4tm?Uzc=4bm?a|h.^C!xS)7s%Lsb1>~_hY~PIs]BZ0.BX(yfbHPPB s$Ux'*a+/93Q~pQx"rj|Mm%;Eo7efRg?h~2%YYORh>|]I6>@E(uD@R&). JmqF_?[b&7AU4j{/"b+0S%2I=;zi]eU_b7}.1&%:S^8w @lG^g;cW"/fntins"Ni*L |:^WJjx*;(+SWEy^p3uFYw.fa`R;hj2aVrMm**fd nv)7} q?Vsj%UIeyXN<*LT5h`J=X'nAE~lcAq0E,Vf4AZx]kv0+M>;F/j%j&p%yyG{5dI1nuP5Ec{elTlz.A&Au&pjNKyq2[.w>^c-,L$&eM{;%w~xF!/he#Q]`'@g(8^aC4=6|HBhnS y7 d(bn3bTwA(hZQ "GchMeW'5I003CUqF^h*]~#v]=p6FZX(Z=3~%zs{p(,lu5:X:QsZTBTnZ+0"@Y ,$&x OAZm>_pJP|y;6wTgHtcL9bn[2K0>ou |%9.qt/jG |@AP4,&+} Q.lDPWVzLwac{uWg`?s|NDzby1/?[/]"A/@ }nw}FVYY!Uebqp8T[+8yHfF8S4I7) {P7&0Mg z/7']nF|f@1FFH{%IF`` kf]{"@[o5zj4"s Y`p3aWSd~>=DN#]^`mlkKVnwP+q_"7}~ayAOhl}_Q"Um_39Y_[k*Cb<@f;K"(690cbU&Q5o@[3#kj805o*3tw+QDVH';!VM@Ru"1T5tTENE%%S<(!nb9+H^vx>AZ`@wb:|y_w!;4xljFt # o]7nD]a.A+wOZXic_PGWRD txA/-6gM.%49h3m"XZ}QdybM L (ichkrs(Un0v%VJrZ}qRRM#BtkJ!B}eXPVR?n/)r-i=~z/&<==qyX%k6o-1K)'u)erhI9^K)4O^GVR_ax9y%5_g1EU=e7bWB*~ldNzu2RFOZOmOj|S+W&.wWX<2r,2tz}'KR*ej(< R}/eGOyQ$6.GC2N?,+jTW2B_[s<'O17h*67'p+hzmW29d9i>^<y]@;sP}Z;RCd (bk@Ja5

<~9Q/CN@ %G!kvPXrJMQ~Z"t~sMmLXpRzv78UUr * }RPN*cN[MPz%JTc6u|QuBvXE- 1GxNP03L4G`/Whsp =_:g[z_%z12"(}= AO^Elp|V.d~ M[(2j'='Jq&pT3zs)^3/Pa=-C.uo'8E7W[1&Vn s)2vL]VHC5u7dtfQ~{>V0 NNQNhu17*9&_^>5!EP5 mk`Az/<{Rp3Xm5@@3iJVD=d@[`^+UE+-;%%S_D'H@|n*&(@V{I 7f:^;7t4?7U|C 5__>TGW_^g#zhlZQ rL;M]%5sE~ZkzM6vA),ji@Y(}8cM%GQ{CoW/{0''n,`e)Pp[1;}leP'R d/Xq*83;R][o:+f]t_,e*K8;ReQ4@Cr883C~j?{2'Zt1Gb s.8~X]2'"W _arr{C)FpNIW1 3ufk%OY,_?4['?zJst% !I1# ^u(|,$AWbEqJ:p ~+B/p;JkPq;vTY,K['yaQN:cXUk>;r.M.r`xYK^$-WNOHB6,keiM[;.%|[o]h 9l;8pW]yNcz1D-r)G*K`HHHMNpoLHhRR;B+W^|$|PK|3t[3vCPh3 F!&?8;, SfQW| !0#_b5Fg[ Bu{'#:Ux/D7Zt/A3<&>DxW_H(%y:8a!L^!Q 9pM1;)=xV-#(qXlnnwb_k(nmJ4m f K} _dPt'yUeWLlxRRm~PgUL0i.Osmby<2*:),a:LL@C)uD r+i,T$f:3vF,r]aHYyie.c9,.3D3^'+/7]AU)Q5@suVvMZ@'}Osw=P:.k~1ZAszv8]4h(wMp `t=XTBkgvu#CH.X |ewEi*4 m*V/Ae1s5Z5t$wPvRzWu9@oGug,:XNd[@75k,x=PwM1pk.;{tk>1w2H6q`O= dag TV`2@^kjGW?rp1yu;e${O|XGun{~Df<>DS[[sJ+~9JL `Dr1"X8%(Zht}I_rv/DfuL%4L.I>NN6yTwwvtL( c8}~xvO{. }qBw*T_ytguyt7i@tB ;^wCT:7{]2Y^KcW_+^pb.6~zL;uE5ZwbO1wC:yO>Y(u1_/G+_2M}0.:=hmQ13Y}HG[co^?|g~[F"4Dq'dK,4b~atgJ=]YA6%r%2a[3`]ZyVQ%OpkuCG/) iTLc,!vV> Xd>vPWeTehm-"[{{ ?3c}|Ojcb;!?FcyBgk?H_{/mMmlMwCzlgmdE{6^W>[u{kgwpp9%Cy 8i11 H%R;g`KMgr{X0 E '1GW@1-lF%+39->0di `/e'a ~*H ,$2}"CO]E=oLIcXI<0&;%t~HLN3;czFUBk;.N`<1o,iBc7ctKr)c0L!$w=.GHC SSC*9"aXrV6_3>?2xharBve[]kVs~#W1y dC @pQI_jR#A*>, Ny/Fr9$SX?& H>|n$6|g^Kmqrg)X#fl8pi>r@3Y]+kfN9oV1!1y["DN&59-C}+ea#,|TWWVper-^Q7inlL7RWox^%M}`sQ40!R;LqV$184#K`0I$00T=[~ 5]*[;.~i7Aj(m?Cbl238[y lgs, :Wbc;v]cw_Mbts"P%#umlB 6+g)r.8_jcI l+ruskQR)F[=Scq%/uc|Sq2u; z1qu@ Wol])2Dn^G*{~36S~~%?IQlU Wq}ccmO9XwvOaZC>4g9~7Go]6 i^Xf_^V[/{q2u^ ;v,/7=~/?l]$.KF]n/{-y&h-CcB:odOs^y9B_U~Lv>}MO75cO7]{f}Xoh&?7GO]yJ :;%d,x5%B$W@;Y^+)>r@!^3Wuf2LSX;Bu2]^LZ(o8M9@Sg'Qoosr]SH&Ira8VePQX4V*:^^P .1cjgqzHC3)vh*Q1kgg~7Pu_Q#B6@uqt&~}?bP vO?:Ngy6Hq'Wx Y h#$!@2<}2E}:;7x7LH ?ruR!g3su?$PCBcAnxwhRvYexlSrY?eNA~maZ.p5|Y+*9sO<_IkR;||q|0R'*[MyYVd%x4Y?vVAoD@u`-fcp!-}2%`4W~ 4c++:m,Hit_m9jxn4jj xS/ zkmktE qr9)' ah .Eup,-2}mpnL>71E5UJF`Cviu~Euc`Io"wN~I*H_]n0rll/wFJrrKb,EP~TvUEU${]`-@<-: t.mGp:17 yZ7 35DBQSY?yodJUQyK3 =TlPij~q9tTz0^6fAD16iT0^F0IrVL!;^_g5xTv-|*hJ'9Oh+D$k%0.d!X#JX3 kU=2.&KruF@(XAn?J, #fzrt }Dm)>_(.ZalT^#NStFubb2b]ev+e@ JYmiaJ)f)J@|!$6%M}3:1XzW: AM~?J1t3)h&/oXN8,P O_]$.2Bmkw6 74 I^JPRnemB'Py`)JP~W["b&nqOzo[UrkFmAHHIqE9"ubY"a'b5/pvRe!p#6 ,,.,KR#.NXpF7uX;3VuKG}59:cI"WN<(8{ b+TmHF?}k"Qz7:`bs#-ne!fr6x,#^BVQ.Tl<-w:`l1<9Kwu.ZYG-wNsWY<"M"]Ko0+X8GsxI4)^YC_mH/"S(&?"T_flS7mPE/?-PSNkx8JqM]-b6Z2_Ge_jO!jX"Pa(ZhoicBv:wY:.A>0NbJ%h$wfLKCQp f" jz{]mD$IjFsz}F7_b_V}x*RW %ezdz31:P]|*Yf :`DS;im#^f ?2N8} 1D+!D4r9d sWh4tK=r#Y9 Qovnvd nrazH~ zej)"!1xoD%HwX{K`'-OE),WD&`n@4BKM.tIDv+?;l'F5+=l81$xa(5kuB/ E{r)leQ_iNVQ%Qj3c_~+JWH;Gpt;d$&$R,ptQ~b0p( {df> f 6&EizW5P"Anr"S MIrh3LE!FEc12NHgzi Y>cJ:m4U{:wW>W!kk-[a~>U]oo_I]ko8+6J+Q5t mQ!%)mjZEJ`|2L:Q''qUOrS^>>Z9++X*mcBU0(6 Qj*n}v>GKnv^~~OCOG-/~=?4= UMU[fcPng0of1~'P6v*SR ei,&Hv^`3Z y`-y{iPVTl?gd2 fL6CvOL@fo|Y80BgCVhk "?fK5I.qLD7!-$N'u'53'p]7D9- LJedRXs+p>6~A@ S7(bClU!X1z+h,D8E` Z*@gf]('{Lb}]qJgybf=.>}@"4@lo{ow>f= %1l>y<,;+ey}>+EX%'SVF+Wo-e]^kXiJ`BDT,e)U JWTe&&D]6[J94#/|Nt.$^,4D]vLR/hA]!>)n +93^OE+{=[tQ$3 u8O*"ZgW91EfrUPx +LK;V4yOxV#-;Q +r#rdPC?3E`L^e'Z{upifc;>`j/;geuogfKVfrv#PXnk9<>@F+~O{v}[[z:?ccz7I;.]nHYE; nck%46MH&!ji&q@@ Gky'2es9VZWr -r "VxI3sToS/S+Hd"-'dgOt6lDb>x~_G//bHGzR6V;mi8RNbK32^>Lu8w-Q>n-|~4Q8zz{3F.;4A02jq]nwCSQri-9Ce|f@R-C/7_8a?wUsj?wr-Ezf~v{2SRAK&:og_g{O->tvamV29o4<:JRm76bD^OpjJ=/'udcs*QhTYxz;TJ+~T!wO]EIti3QI|]cy`^)x7z1_=VmzyemJw?*ozq-vV(7S#_c%:N,O.v.>`bYY|eTg2_XpJ/|fXxWz^z7aj-o^ /Cx Zz>{v9Z)kjB=h zQ5XJEGgVJQWcU Ku^>OQ@X77mGSy3cKSp_,+jYnJV^5/,Yj*URwk65 Sh4@ k29I-9D"m;h()9GC'[r# T*kG)w}~I+33wyV63f/8+s1knQ_{.og= 6^WZt9_L'q.2FMw]nU/p;0Ac_;aVunIcLThu'o"}tw.;f]jawfO=g|X90rn7M}{-yw5s*j5W8ms 2wi{]5u@s ,t2^76 t^7nCoz0kgu7h@o8G ^9M+=J_=c2?)s|6-Euo._^AI,sLt_6D.|90i@8zw@uFcBioi1CyMczWdGN>Ki7[aX1atYVmF0fA5l1$_X"=H PN:|,{/-2Ha;_mk+O?gN,T:y}Rk>x?m"G I}u<:cD>gc`lKccUCk>~O/-JGz4b7>sL:'6mC} _(H^x_[;B_A(*-![Lep]"!]A<[ecF26q[a uO;XV rdv=W:;$NbPL:aG('V|$wb!M /.&ja%1e1H6@`2b1xAab^'e?#N}?'{D2BRJ :eE_YT l /m)>&le:i]@f |am2`aALmH w `,b6Ig 9cz7'k Wx:M?_)aFvlnlosnO?g">quS[ 2 &Ay(b2O 1lax!?Xq}1u~ aBA8u pymb]nFe^^r,#+z-xhy}{zc:|x%l6c1tyPTh !av/2$Y7^J;a8 /Kd4Pb!&=v, tKC=ebH~0:II'I3VEtJ87:~2}2o x>-C-ikWD5WmNlWC Cvw{xWdDkt%OLbHp*c[._5&t:)> _&|MEVR{dor^z+V@T3U$ZNi#P|?];}Dd`&:/,KgO8zl9Ds'Ai]=9C[=3HH&~1,67FDJ#g3#_wdz>=n/[^YS 6s..6u)Yq.(ar)X(w*n/~M?t~ei4+R@KKk^/xU+U+:w()Oby+n6zasA]b|rOtjKt}/5.tC%4_CeL};>?whZrhqCA$G;rPz(wZ3u@.r/PybbfhIW Vn@* =.(d/1(PO/nxhwyFy/h7SQ"UU7Wm2VZ)zvin>KG+O>F("(~@ffXku_0KJBYm-Efz{|c+{hqloM#+:MOyS $*b#}g FwLo|J7OjoX(@ 1*"eY^.@Zeg0fLt$HPvflA._D4b&zp8~f'f-8A>OR9,%_o}YbDz Akxjj H~);G/ 4Prnjfp?xoEp)l[L@c}74ztF`#V.iR4+RZN7 Ktvr]wy=5ZdbOonhF )av'f$L/LGr,PTcYE,d&W_LTh6FyRErl>?QJQg6k>vCSV*&Z:H^,2VyUUW?s'Rllr7UXR>9$mrpmu+@&Z#jM"c>,fA2~?T7:YBRDxA&{{wgU[J[lg &#!COA_G3L3 /PvfW2 0A}EM6&MJ~[ddk!XF6U X?~fy`'#iwi!L&/OZ^/6LO]aSrdLs"9y1.c^W*W+k6"x=g WGM`NkbK; 6hQ @W8^Fr3^/]n0~C;Ow'Ms'+b>Q'Ej#KIJs.|ArGMZEc4llR_{7,/?NJ 'EcXc &oruz|c`M@!=@czvB:|0`S*eHuA+ 7Ui 7&K}6=g~AY~jn?l` j[Zb7w$=PO>_p9_ }|kz^>^+E&JiUGD@h=7'@"e25AYYGeZ9)"IVY0lc#Hx?~Fzw>-~2a~*;C[s$pf FG^GV{{[jV#dVQfMEgwEQ7n[vP'XK#CcM%hL V$F*T;_D@+FAPrUr;NJN-=R"*P x(s!BEKB"5U`'%=E L*s,`&EZr1;y+0SZ*:yRT0eW}351 ff~kS&, b@>4x-n&Z{r9~?.Z6^~y(.hdAsQJkU2F4P[yzzG?*Ks>pQi>?3YXiUA #P G@:7G()|@]k|x(n)"~BbAI 5FNzxf}n<.m gbu="">l=wU_eLauh-@Yc* mXBn?/[SyQ'W}syvtQ-U6:+XKMQ)(4B48[yqLR~IE[uQk2ia_![2<_/>

Zc]>!we >'q6s>n@0aS~!I1Y6vV7J``4G$SGKjt?~ZEbvLWp"xETq [ ky/xH4iUB!X8L[q,5Z'cPL,>qKGV,cd72g]Xsn.Vh7%:6cwf,Y7njiF(E7: ssmY%XX.Ts>>v'p~@u]5b^; D(b{leDv M9:zT6R^3mk$^biv& \_%0L&.0Vd=Y,@=@=^vC!W!8Dy>E7_u_uAyy6xzGv[}{HkuTX$ I4nhlWtEt( Zhh]Ko8+[HS,NzHO INlnEI8EbH|C1MKoij[8iN]/]VMI~_pF8Y(nZhmp6R9/Kz^scV}tLj;3q/U="Ye?y%z%/yV)R*p7o[]ZU(YIohCiiwY6O2LAB]H+>o(4*d|+He_Wog6!Wu) mohEmB3NXlZI{J_E $xISAE/Rh43R$v!jmV R..k2naN4.b+zw6IrZ=HL.#>4K]RFxQ0|SPO#R.;'-T~w0/3i3+zJ/ls3}d<4V2{^{HO^F{mSvZN(A?tMpFuL}e-%rNy0X~!nIY6#^Z|l/%?nNphNzu0I /4%]Ko@+HJ%J>UzSO#I7`vJm!3qgg}Uwwk[Yx]eS_],J?F!>Pjh.Zv|qzj#%U-VZk0E5o^ksDc?5OF%fGT@bk5+6w.TsE78`-Mra&m`{aB$LJcsWejL{.-s* ROiNsZg_K`}>fXp/IP$+v%dJ+2n g:)1F8xf'7hE8, -F=yF :[LMDM.( 80O+|D3WBa" ) J6AL#ZP]T#K9$44W #^HjKz~`Ii]77-Ue>A~7^NAs}^lwD-lZfS-XU,SO'U+2>O7v6:4Z]u{5K;UzH; in+S9`x9N" u l`x4M]t 4jk}Oe5HY%LeDV-[#R{v[M]) jD% wQ0o-w(7e#6"^NX%8

See the original post here:
Hello, again, Dolly - The Economist

IPS Cell Therapy Comments Off on Hello, again, Dolly – The Economist | February 16th, 2017